Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,28981899,LC50,The carbazole aminoalcohols exhibited potent protoscolicidal activity with LC50 values ranging from 18.2 to 34.3 μM.,In vitro and in vivo efficacies of novel carbazole aminoalcohols in the treatment of cystic echinococcosis. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28981899/),μM,18.2 to 34.3,2142,DB00518,Albendazole
>,28981899,oral bioavailability,Pharmacokinetic profiling of compounds 2 and 24 revealed low clearance and decent oral bioavailability (>70%).,In vitro and in vivo efficacies of novel carbazole aminoalcohols in the treatment of cystic echinococcosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28981899/),%,70,2143,DB00518,Albendazole
,12902210,absorption half-lives (t(1/2ab)),"After intramuscular injection, enrofloxacin was rapidly absorbed in control and albendazole-treated lactating goats with absorption half-lives (t(1/2ab)) 0.43 and 0.39 h, respectively.",Influence of albendazole on the disposition kinetics and milk antimicrobial equivalent activity of enrofloxacin in lactating goats. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12902210/),h,0.43,11094,DB00518,Albendazole
,12902210,absorption half-lives (t(1/2ab)),"After intramuscular injection, enrofloxacin was rapidly absorbed in control and albendazole-treated lactating goats with absorption half-lives (t(1/2ab)) 0.43 and 0.39 h, respectively.",Influence of albendazole on the disposition kinetics and milk antimicrobial equivalent activity of enrofloxacin in lactating goats. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12902210/),h,0.39,11095,DB00518,Albendazole
,12902210,peaks of serum concentration (C(max)),"The mean peaks of serum concentration (C(max)) were 0.68 and 0.65 mcg ml(-1) attained at (t(max)) 1.08 and 1.12 h, before and after albendazole dosing, respectively.",Influence of albendazole on the disposition kinetics and milk antimicrobial equivalent activity of enrofloxacin in lactating goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12902210/),[mcg] / [ml],0.68,11096,DB00518,Albendazole
,12902210,peaks of serum concentration (C(max)),"The mean peaks of serum concentration (C(max)) were 0.68 and 0.65 mcg ml(-1) attained at (t(max)) 1.08 and 1.12 h, before and after albendazole dosing, respectively.",Influence of albendazole on the disposition kinetics and milk antimicrobial equivalent activity of enrofloxacin in lactating goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12902210/),[mcg] / [ml],0.65,11097,DB00518,Albendazole
,12902210,t(max)),"The mean peaks of serum concentration (C(max)) were 0.68 and 0.65 mcg ml(-1) attained at (t(max)) 1.08 and 1.12 h, before and after albendazole dosing, respectively.",Influence of albendazole on the disposition kinetics and milk antimicrobial equivalent activity of enrofloxacin in lactating goats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12902210/),h,1.08,11098,DB00518,Albendazole
,12902210,t(max)),"The mean peaks of serum concentration (C(max)) were 0.68 and 0.65 mcg ml(-1) attained at (t(max)) 1.08 and 1.12 h, before and after albendazole dosing, respectively.",Influence of albendazole on the disposition kinetics and milk antimicrobial equivalent activity of enrofloxacin in lactating goats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12902210/),h,1.12,11099,DB00518,Albendazole
,12902210,systemic bioavailability,The systemic bioavailability of enrofloxacin was significantly decreased from 110.16 to 84.38% in albendazole-treated lactating goats.,Influence of albendazole on the disposition kinetics and milk antimicrobial equivalent activity of enrofloxacin in lactating goats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12902210/),%,110.16,11100,DB00518,Albendazole
,12902210,systemic bioavailability,The systemic bioavailability of enrofloxacin was significantly decreased from 110.16 to 84.38% in albendazole-treated lactating goats.,Influence of albendazole on the disposition kinetics and milk antimicrobial equivalent activity of enrofloxacin in lactating goats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12902210/),%,84.38,11101,DB00518,Albendazole
,21797012,LODs,The LODs ranged from 0.08 to 2.0 microg/kg and the LOQs from 0.3 to 5.0 microg/kg.,Simultaneous determination of benzimidazoles and their metabolites in plasma using high-performance liquid chromatography/tandem mass spectrometry: application to pharmacokinetic studies in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21797012/),[μg] / [kg],0.08 to 2.0,12834,DB00518,Albendazole
,21797012,LOQs,The LODs ranged from 0.08 to 2.0 microg/kg and the LOQs from 0.3 to 5.0 microg/kg.,Simultaneous determination of benzimidazoles and their metabolites in plasma using high-performance liquid chromatography/tandem mass spectrometry: application to pharmacokinetic studies in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21797012/),[μg] / [kg],0.3 to 5.0,12835,DB00518,Albendazole
,30947125,recovery,"Importantly, a simple, one-step protein precipitation and extraction method was used to extract the four compounds efficiently with a recovery in the range of 79.88 ± 5.02%-90.71 ± 5.13%, 85.72 ± 7.22%-93.17 ± 5.55%, 94.38 ± 7.35%-101.00 ± 8.88% and 94.38 ± 7.35%-99.87 ± 10.22% in plasma and organs for DOX, DEC, ABZ-OZ and ABZ-ON, respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),%,79.88,13278,DB00518,Albendazole
,30947125,recovery,"Importantly, a simple, one-step protein precipitation and extraction method was used to extract the four compounds efficiently with a recovery in the range of 79.88 ± 5.02%-90.71 ± 5.13%, 85.72 ± 7.22%-93.17 ± 5.55%, 94.38 ± 7.35%-101.00 ± 8.88% and 94.38 ± 7.35%-99.87 ± 10.22% in plasma and organs for DOX, DEC, ABZ-OZ and ABZ-ON, respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),%,90.71,13279,DB00518,Albendazole
,30947125,recovery,"Importantly, a simple, one-step protein precipitation and extraction method was used to extract the four compounds efficiently with a recovery in the range of 79.88 ± 5.02%-90.71 ± 5.13%, 85.72 ± 7.22%-93.17 ± 5.55%, 94.38 ± 7.35%-101.00 ± 8.88% and 94.38 ± 7.35%-99.87 ± 10.22% in plasma and organs for DOX, DEC, ABZ-OZ and ABZ-ON, respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),%,85.72,13280,DB00518,Albendazole
,30947125,recovery,"Importantly, a simple, one-step protein precipitation and extraction method was used to extract the four compounds efficiently with a recovery in the range of 79.88 ± 5.02%-90.71 ± 5.13%, 85.72 ± 7.22%-93.17 ± 5.55%, 94.38 ± 7.35%-101.00 ± 8.88% and 94.38 ± 7.35%-99.87 ± 10.22% in plasma and organs for DOX, DEC, ABZ-OZ and ABZ-ON, respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),%,93.17,13281,DB00518,Albendazole
,30947125,recovery,"Importantly, a simple, one-step protein precipitation and extraction method was used to extract the four compounds efficiently with a recovery in the range of 79.88 ± 5.02%-90.71 ± 5.13%, 85.72 ± 7.22%-93.17 ± 5.55%, 94.38 ± 7.35%-101.00 ± 8.88% and 94.38 ± 7.35%-99.87 ± 10.22% in plasma and organs for DOX, DEC, ABZ-OZ and ABZ-ON, respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),%,94.38,13282,DB00518,Albendazole
,30947125,recovery,"Importantly, a simple, one-step protein precipitation and extraction method was used to extract the four compounds efficiently with a recovery in the range of 79.88 ± 5.02%-90.71 ± 5.13%, 85.72 ± 7.22%-93.17 ± 5.55%, 94.38 ± 7.35%-101.00 ± 8.88% and 94.38 ± 7.35%-99.87 ± 10.22% in plasma and organs for DOX, DEC, ABZ-OZ and ABZ-ON, respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),%,101.00,13283,DB00518,Albendazole
,30947125,recovery,"Importantly, a simple, one-step protein precipitation and extraction method was used to extract the four compounds efficiently with a recovery in the range of 79.88 ± 5.02%-90.71 ± 5.13%, 85.72 ± 7.22%-93.17 ± 5.55%, 94.38 ± 7.35%-101.00 ± 8.88% and 94.38 ± 7.35%-99.87 ± 10.22% in plasma and organs for DOX, DEC, ABZ-OZ and ABZ-ON, respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),%,99.87,13284,DB00518,Albendazole
,30947125,run time,"Separation of all analytes was performed on a Xselect CSH™ C18 HPLC column (Waters, 3.0 x 150 mm, 3.5 μm particle size) with gradient elution employing a mobile phase consisting of 0.1% v/v formic acid in water and methanol with a run time of 20 min.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),min,20,13285,DB00518,Albendazole
,30947125,m/z,"Quantification was carried out employing a single, quadruple MS detector operated with single ion monitoring (SIM) mode and the ion transitions at m/z of 445.4, 200.2, 282.3 and 298.3 for DOX, DEC, ABZ-OX and ABZ-ON respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),,445.4,13286,DB00518,Albendazole
,30947125,m/z,"Quantification was carried out employing a single, quadruple MS detector operated with single ion monitoring (SIM) mode and the ion transitions at m/z of 445.4, 200.2, 282.3 and 298.3 for DOX, DEC, ABZ-OX and ABZ-ON respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),,200.2,13287,DB00518,Albendazole
,30947125,m/z,"Quantification was carried out employing a single, quadruple MS detector operated with single ion monitoring (SIM) mode and the ion transitions at m/z of 445.4, 200.2, 282.3 and 298.3 for DOX, DEC, ABZ-OX and ABZ-ON respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),,282.3,13288,DB00518,Albendazole
,30947125,m/z,"Quantification was carried out employing a single, quadruple MS detector operated with single ion monitoring (SIM) mode and the ion transitions at m/z of 445.4, 200.2, 282.3 and 298.3 for DOX, DEC, ABZ-OX and ABZ-ON respectively.","New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30947125/),,298.3,13289,DB00518,Albendazole
,9279580,Tmax,"ABZSO pharmacokinetic profiles following ABZ or RBZ administration were similar, although the Tmax (1.83 +/- 0.30 and 0.41 +/- 0.28, respectively) were significantly different (P < 0.01).",Albendazole versus ricobendazole (albendazole-sulphoxide) against enteral and parenteral stages of Trichinella spiralis in mice. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9279580/),,1.83,16755,DB00518,Albendazole
,9279580,Tmax,"ABZSO pharmacokinetic profiles following ABZ or RBZ administration were similar, although the Tmax (1.83 +/- 0.30 and 0.41 +/- 0.28, respectively) were significantly different (P < 0.01).",Albendazole versus ricobendazole (albendazole-sulphoxide) against enteral and parenteral stages of Trichinella spiralis in mice. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9279580/),,0.41,16756,DB00518,Albendazole
,11421376,Cmax,Cmax was 0.21+/-0.14 mg/L after 5 mg/kg and 0.39+/-0.19 mg/L after 30 mg/kg albendazole (P = 0.217).,Effect of dose increase or cimetidine co-administration on albendazole bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11421376/),[mg] / [l],0.21,17083,DB00518,Albendazole
,11421376,Cmax,Cmax was 0.21+/-0.14 mg/L after 5 mg/kg and 0.39+/-0.19 mg/L after 30 mg/kg albendazole (P = 0.217).,Effect of dose increase or cimetidine co-administration on albendazole bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11421376/),[mg] / [l],0.39,17084,DB00518,Albendazole
,11421376,elimination half-life,Cimetidine tended to decrease Cmax by 52% (P = 0.109) and significantly inhibited ABZSX breakdown as indicated by the prolongation of ABZSX elimination half-life from 7.4+/-3.3 hr to 19.0+/-11.7 hr (P = 0.028).,Effect of dose increase or cimetidine co-administration on albendazole bioavailability. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11421376/),h,7.4,17085,DB00518,Albendazole
,11421376,elimination half-life,Cimetidine tended to decrease Cmax by 52% (P = 0.109) and significantly inhibited ABZSX breakdown as indicated by the prolongation of ABZSX elimination half-life from 7.4+/-3.3 hr to 19.0+/-11.7 hr (P = 0.028).,Effect of dose increase or cimetidine co-administration on albendazole bioavailability. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11421376/),h,19.0,17086,DB00518,Albendazole
,22227164,absorption half-life (t₁/₂ka),"The absorption half-life (t₁/₂ka) of ABZSO was 3.86 h at 10 °C and 1.29 h at 25 °C, whereas the elimination half-life (t₁/₂ke) was 16.34 h at 10 °C and 6.72 h at 25 °C; the maximum plasma concentration (C(max)) and the time-point of maximum plasma concentration (T(p)) were calculated as 3.20 μg mL(-1) and 10.58 h at 10 °C, 4.39 μg mL(-1) and 3.80 h at 25 °C.",Pharmacokinetics and tissue residues of hydrochloric acid albendazole sulfoxide and its metabolites in crucian carp (Carassius auratus) after oral administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22227164/),h,3.86,18684,DB00518,Albendazole
,22227164,absorption half-life (t₁/₂ka),"The absorption half-life (t₁/₂ka) of ABZSO was 3.86 h at 10 °C and 1.29 h at 25 °C, whereas the elimination half-life (t₁/₂ke) was 16.34 h at 10 °C and 6.72 h at 25 °C; the maximum plasma concentration (C(max)) and the time-point of maximum plasma concentration (T(p)) were calculated as 3.20 μg mL(-1) and 10.58 h at 10 °C, 4.39 μg mL(-1) and 3.80 h at 25 °C.",Pharmacokinetics and tissue residues of hydrochloric acid albendazole sulfoxide and its metabolites in crucian carp (Carassius auratus) after oral administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22227164/),h,1.29,18685,DB00518,Albendazole
,22227164,elimination half-life (t₁/₂ke),"The absorption half-life (t₁/₂ka) of ABZSO was 3.86 h at 10 °C and 1.29 h at 25 °C, whereas the elimination half-life (t₁/₂ke) was 16.34 h at 10 °C and 6.72 h at 25 °C; the maximum plasma concentration (C(max)) and the time-point of maximum plasma concentration (T(p)) were calculated as 3.20 μg mL(-1) and 10.58 h at 10 °C, 4.39 μg mL(-1) and 3.80 h at 25 °C.",Pharmacokinetics and tissue residues of hydrochloric acid albendazole sulfoxide and its metabolites in crucian carp (Carassius auratus) after oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22227164/),h,16.34,18686,DB00518,Albendazole
,22227164,elimination half-life (t₁/₂ke),"The absorption half-life (t₁/₂ka) of ABZSO was 3.86 h at 10 °C and 1.29 h at 25 °C, whereas the elimination half-life (t₁/₂ke) was 16.34 h at 10 °C and 6.72 h at 25 °C; the maximum plasma concentration (C(max)) and the time-point of maximum plasma concentration (T(p)) were calculated as 3.20 μg mL(-1) and 10.58 h at 10 °C, 4.39 μg mL(-1) and 3.80 h at 25 °C.",Pharmacokinetics and tissue residues of hydrochloric acid albendazole sulfoxide and its metabolites in crucian carp (Carassius auratus) after oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22227164/),h,6.72,18687,DB00518,Albendazole
,22227164,maximum plasma concentration (C(max)),"The absorption half-life (t₁/₂ka) of ABZSO was 3.86 h at 10 °C and 1.29 h at 25 °C, whereas the elimination half-life (t₁/₂ke) was 16.34 h at 10 °C and 6.72 h at 25 °C; the maximum plasma concentration (C(max)) and the time-point of maximum plasma concentration (T(p)) were calculated as 3.20 μg mL(-1) and 10.58 h at 10 °C, 4.39 μg mL(-1) and 3.80 h at 25 °C.",Pharmacokinetics and tissue residues of hydrochloric acid albendazole sulfoxide and its metabolites in crucian carp (Carassius auratus) after oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22227164/),[μg] / [ml],3.20,18688,DB00518,Albendazole
,22227164,maximum plasma concentration (C(max)),"The absorption half-life (t₁/₂ka) of ABZSO was 3.86 h at 10 °C and 1.29 h at 25 °C, whereas the elimination half-life (t₁/₂ke) was 16.34 h at 10 °C and 6.72 h at 25 °C; the maximum plasma concentration (C(max)) and the time-point of maximum plasma concentration (T(p)) were calculated as 3.20 μg mL(-1) and 10.58 h at 10 °C, 4.39 μg mL(-1) and 3.80 h at 25 °C.",Pharmacokinetics and tissue residues of hydrochloric acid albendazole sulfoxide and its metabolites in crucian carp (Carassius auratus) after oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22227164/),[μg] / [ml],4.39,18689,DB00518,Albendazole
,22227164,time-point of maximum plasma concentration (T(p)),"The absorption half-life (t₁/₂ka) of ABZSO was 3.86 h at 10 °C and 1.29 h at 25 °C, whereas the elimination half-life (t₁/₂ke) was 16.34 h at 10 °C and 6.72 h at 25 °C; the maximum plasma concentration (C(max)) and the time-point of maximum plasma concentration (T(p)) were calculated as 3.20 μg mL(-1) and 10.58 h at 10 °C, 4.39 μg mL(-1) and 3.80 h at 25 °C.",Pharmacokinetics and tissue residues of hydrochloric acid albendazole sulfoxide and its metabolites in crucian carp (Carassius auratus) after oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22227164/),h,10.58,18690,DB00518,Albendazole
,22227164,time-point of maximum plasma concentration (T(p)),"The absorption half-life (t₁/₂ka) of ABZSO was 3.86 h at 10 °C and 1.29 h at 25 °C, whereas the elimination half-life (t₁/₂ke) was 16.34 h at 10 °C and 6.72 h at 25 °C; the maximum plasma concentration (C(max)) and the time-point of maximum plasma concentration (T(p)) were calculated as 3.20 μg mL(-1) and 10.58 h at 10 °C, 4.39 μg mL(-1) and 3.80 h at 25 °C.",Pharmacokinetics and tissue residues of hydrochloric acid albendazole sulfoxide and its metabolites in crucian carp (Carassius auratus) after oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22227164/),[μg] / [ml],4.39,18691,DB00518,Albendazole
,22227164,time-point of maximum plasma concentration (T(p)),"The absorption half-life (t₁/₂ka) of ABZSO was 3.86 h at 10 °C and 1.29 h at 25 °C, whereas the elimination half-life (t₁/₂ke) was 16.34 h at 10 °C and 6.72 h at 25 °C; the maximum plasma concentration (C(max)) and the time-point of maximum plasma concentration (T(p)) were calculated as 3.20 μg mL(-1) and 10.58 h at 10 °C, 4.39 μg mL(-1) and 3.80 h at 25 °C.",Pharmacokinetics and tissue residues of hydrochloric acid albendazole sulfoxide and its metabolites in crucian carp (Carassius auratus) after oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22227164/),h,3.80,18692,DB00518,Albendazole
,22227164,distribution volume (V(d)/F),"The distribution volume (V(d)/F) of ABZSO was estimated to be 1.99 L kg(-1) at 10 °C and 1.53 L kg(-1) at 25 °C; the total body clearance (CL(b)) of ABZSO were computed as 0.08 and 0.19 L/(h kg) at 10 and 25 °C, respectively; the areas under the concentration-time curve (AUC) was 118.22 μg mL(-1)h at 10 °C and 63.12 μg mL(-1)h at 25 °C.",Pharmacokinetics and tissue residues of hydrochloric acid albendazole sulfoxide and its metabolites in crucian carp (Carassius auratus) after oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22227164/),[l] / [kg],1.99,18693,DB00518,Albendazole
,22227164,distribution volume (V(d)/F),"The distribution volume (V(d)/F) of ABZSO was estimated to be 1.99 L kg(-1) at 10 °C and 1.53 L kg(-1) at 25 °C; the total body clearance (CL(b)) of ABZSO were computed as 0.08 and 0.19 L/(h kg) at 10 and 25 °C, respectively; the areas under the concentration-time curve (AUC) was 118.22 μg mL(-1)h at 10 °C and 63.12 μg mL(-1)h at 25 °C.",Pharmacokinetics and tissue residues of hydrochloric acid albendazole sulfoxide and its metabolites in crucian carp (Carassius auratus) after oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22227164/),[l] / [kg],1.53,18694,DB00518,Albendazole
,22227164,total body clearance (CL(b)),"The distribution volume (V(d)/F) of ABZSO was estimated to be 1.99 L kg(-1) at 10 °C and 1.53 L kg(-1) at 25 °C; the total body clearance (CL(b)) of ABZSO were computed as 0.08 and 0.19 L/(h kg) at 10 and 25 °C, respectively; the areas under the concentration-time curve (AUC) was 118.22 μg mL(-1)h at 10 °C and 63.12 μg mL(-1)h at 25 °C.",Pharmacokinetics and tissue residues of hydrochloric acid albendazole sulfoxide and its metabolites in crucian carp (Carassius auratus) after oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22227164/),[l] / [h·kg],0.08,18695,DB00518,Albendazole
,22227164,total body clearance (CL(b)),"The distribution volume (V(d)/F) of ABZSO was estimated to be 1.99 L kg(-1) at 10 °C and 1.53 L kg(-1) at 25 °C; the total body clearance (CL(b)) of ABZSO were computed as 0.08 and 0.19 L/(h kg) at 10 and 25 °C, respectively; the areas under the concentration-time curve (AUC) was 118.22 μg mL(-1)h at 10 °C and 63.12 μg mL(-1)h at 25 °C.",Pharmacokinetics and tissue residues of hydrochloric acid albendazole sulfoxide and its metabolites in crucian carp (Carassius auratus) after oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22227164/),[l] / [h·kg],0.19,18696,DB00518,Albendazole
,22227164,areas under the concentration-time curve (AUC),"The distribution volume (V(d)/F) of ABZSO was estimated to be 1.99 L kg(-1) at 10 °C and 1.53 L kg(-1) at 25 °C; the total body clearance (CL(b)) of ABZSO were computed as 0.08 and 0.19 L/(h kg) at 10 and 25 °C, respectively; the areas under the concentration-time curve (AUC) was 118.22 μg mL(-1)h at 10 °C and 63.12 μg mL(-1)h at 25 °C.",Pharmacokinetics and tissue residues of hydrochloric acid albendazole sulfoxide and its metabolites in crucian carp (Carassius auratus) after oral administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22227164/),[μg] / [ml],118.22,18697,DB00518,Albendazole
,22227164,areas under the concentration-time curve (AUC),"The distribution volume (V(d)/F) of ABZSO was estimated to be 1.99 L kg(-1) at 10 °C and 1.53 L kg(-1) at 25 °C; the total body clearance (CL(b)) of ABZSO were computed as 0.08 and 0.19 L/(h kg) at 10 and 25 °C, respectively; the areas under the concentration-time curve (AUC) was 118.22 μg mL(-1)h at 10 °C and 63.12 μg mL(-1)h at 25 °C.",Pharmacokinetics and tissue residues of hydrochloric acid albendazole sulfoxide and its metabolites in crucian carp (Carassius auratus) after oral administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22227164/),[μg] / [ml],63.12,18698,DB00518,Albendazole
,22227164,C(max),"The [Formula: see text] of ABZSO(2) was found to be 6.39 °C at 10 °C and 3.73 h at 25 °C, whereas the [Formula: see text] was 12.86 h at 10 °C and 6.56 h at 25 °C; the C(max) and T(p) of ABZSO(2) was calculated as 0.78 μg mL(-1) and 12.82 h at 10 °C, 1.03 μg mL(-1) and 7.04 h at 25 °C, respectively; the V(d)/F of ABZSO(2) were estimated to be 6.43 L kg(-1) at 10 °C and 4.61 Lkg(-1) at 25 °C; the CL(b) of ABZSO(2) were computed as 0.34 and 0.49 L/(h kg) at 10 °C and 25 °C, respectively; the AUC of ABZSO(2) were 28.86 μg mL(-1)h at 10 °C and 20.52 μg mL(-1)h at 25 °C.",Pharmacokinetics and tissue residues of hydrochloric acid albendazole sulfoxide and its metabolites in crucian carp (Carassius auratus) after oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22227164/),[μg] / [ml],0.78,18699,DB00518,Albendazole
,22227164,C(max),"The [Formula: see text] of ABZSO(2) was found to be 6.39 °C at 10 °C and 3.73 h at 25 °C, whereas the [Formula: see text] was 12.86 h at 10 °C and 6.56 h at 25 °C; the C(max) and T(p) of ABZSO(2) was calculated as 0.78 μg mL(-1) and 12.82 h at 10 °C, 1.03 μg mL(-1) and 7.04 h at 25 °C, respectively; the V(d)/F of ABZSO(2) were estimated to be 6.43 L kg(-1) at 10 °C and 4.61 Lkg(-1) at 25 °C; the CL(b) of ABZSO(2) were computed as 0.34 and 0.49 L/(h kg) at 10 °C and 25 °C, respectively; the AUC of ABZSO(2) were 28.86 μg mL(-1)h at 10 °C and 20.52 μg mL(-1)h at 25 °C.",Pharmacokinetics and tissue residues of hydrochloric acid albendazole sulfoxide and its metabolites in crucian carp (Carassius auratus) after oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22227164/),[μg] / [ml],1.03,18700,DB00518,Albendazole
,22227164,T(p),"The [Formula: see text] of ABZSO(2) was found to be 6.39 °C at 10 °C and 3.73 h at 25 °C, whereas the [Formula: see text] was 12.86 h at 10 °C and 6.56 h at 25 °C; the C(max) and T(p) of ABZSO(2) was calculated as 0.78 μg mL(-1) and 12.82 h at 10 °C, 1.03 μg mL(-1) and 7.04 h at 25 °C, respectively; the V(d)/F of ABZSO(2) were estimated to be 6.43 L kg(-1) at 10 °C and 4.61 Lkg(-1) at 25 °C; the CL(b) of ABZSO(2) were computed as 0.34 and 0.49 L/(h kg) at 10 °C and 25 °C, respectively; the AUC of ABZSO(2) were 28.86 μg mL(-1)h at 10 °C and 20.52 μg mL(-1)h at 25 °C.",Pharmacokinetics and tissue residues of hydrochloric acid albendazole sulfoxide and its metabolites in crucian carp (Carassius auratus) after oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22227164/),h,12.82,18701,DB00518,Albendazole
,22227164,T(p),"The [Formula: see text] of ABZSO(2) was found to be 6.39 °C at 10 °C and 3.73 h at 25 °C, whereas the [Formula: see text] was 12.86 h at 10 °C and 6.56 h at 25 °C; the C(max) and T(p) of ABZSO(2) was calculated as 0.78 μg mL(-1) and 12.82 h at 10 °C, 1.03 μg mL(-1) and 7.04 h at 25 °C, respectively; the V(d)/F of ABZSO(2) were estimated to be 6.43 L kg(-1) at 10 °C and 4.61 Lkg(-1) at 25 °C; the CL(b) of ABZSO(2) were computed as 0.34 and 0.49 L/(h kg) at 10 °C and 25 °C, respectively; the AUC of ABZSO(2) were 28.86 μg mL(-1)h at 10 °C and 20.52 μg mL(-1)h at 25 °C.",Pharmacokinetics and tissue residues of hydrochloric acid albendazole sulfoxide and its metabolites in crucian carp (Carassius auratus) after oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22227164/),h,7.04,18702,DB00518,Albendazole
,22227164,V(d)/F,"The [Formula: see text] of ABZSO(2) was found to be 6.39 °C at 10 °C and 3.73 h at 25 °C, whereas the [Formula: see text] was 12.86 h at 10 °C and 6.56 h at 25 °C; the C(max) and T(p) of ABZSO(2) was calculated as 0.78 μg mL(-1) and 12.82 h at 10 °C, 1.03 μg mL(-1) and 7.04 h at 25 °C, respectively; the V(d)/F of ABZSO(2) were estimated to be 6.43 L kg(-1) at 10 °C and 4.61 Lkg(-1) at 25 °C; the CL(b) of ABZSO(2) were computed as 0.34 and 0.49 L/(h kg) at 10 °C and 25 °C, respectively; the AUC of ABZSO(2) were 28.86 μg mL(-1)h at 10 °C and 20.52 μg mL(-1)h at 25 °C.",Pharmacokinetics and tissue residues of hydrochloric acid albendazole sulfoxide and its metabolites in crucian carp (Carassius auratus) after oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22227164/),[l] / [kg],6.43,18703,DB00518,Albendazole
,22227164,V(d)/F,"The [Formula: see text] of ABZSO(2) was found to be 6.39 °C at 10 °C and 3.73 h at 25 °C, whereas the [Formula: see text] was 12.86 h at 10 °C and 6.56 h at 25 °C; the C(max) and T(p) of ABZSO(2) was calculated as 0.78 μg mL(-1) and 12.82 h at 10 °C, 1.03 μg mL(-1) and 7.04 h at 25 °C, respectively; the V(d)/F of ABZSO(2) were estimated to be 6.43 L kg(-1) at 10 °C and 4.61 Lkg(-1) at 25 °C; the CL(b) of ABZSO(2) were computed as 0.34 and 0.49 L/(h kg) at 10 °C and 25 °C, respectively; the AUC of ABZSO(2) were 28.86 μg mL(-1)h at 10 °C and 20.52 μg mL(-1)h at 25 °C.",Pharmacokinetics and tissue residues of hydrochloric acid albendazole sulfoxide and its metabolites in crucian carp (Carassius auratus) after oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22227164/),1/[lkg],4.61,18704,DB00518,Albendazole
,22227164,CL(b),"The [Formula: see text] of ABZSO(2) was found to be 6.39 °C at 10 °C and 3.73 h at 25 °C, whereas the [Formula: see text] was 12.86 h at 10 °C and 6.56 h at 25 °C; the C(max) and T(p) of ABZSO(2) was calculated as 0.78 μg mL(-1) and 12.82 h at 10 °C, 1.03 μg mL(-1) and 7.04 h at 25 °C, respectively; the V(d)/F of ABZSO(2) were estimated to be 6.43 L kg(-1) at 10 °C and 4.61 Lkg(-1) at 25 °C; the CL(b) of ABZSO(2) were computed as 0.34 and 0.49 L/(h kg) at 10 °C and 25 °C, respectively; the AUC of ABZSO(2) were 28.86 μg mL(-1)h at 10 °C and 20.52 μg mL(-1)h at 25 °C.",Pharmacokinetics and tissue residues of hydrochloric acid albendazole sulfoxide and its metabolites in crucian carp (Carassius auratus) after oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22227164/),[l] / [h·kg],0.34,18705,DB00518,Albendazole
,22227164,CL(b),"The [Formula: see text] of ABZSO(2) was found to be 6.39 °C at 10 °C and 3.73 h at 25 °C, whereas the [Formula: see text] was 12.86 h at 10 °C and 6.56 h at 25 °C; the C(max) and T(p) of ABZSO(2) was calculated as 0.78 μg mL(-1) and 12.82 h at 10 °C, 1.03 μg mL(-1) and 7.04 h at 25 °C, respectively; the V(d)/F of ABZSO(2) were estimated to be 6.43 L kg(-1) at 10 °C and 4.61 Lkg(-1) at 25 °C; the CL(b) of ABZSO(2) were computed as 0.34 and 0.49 L/(h kg) at 10 °C and 25 °C, respectively; the AUC of ABZSO(2) were 28.86 μg mL(-1)h at 10 °C and 20.52 μg mL(-1)h at 25 °C.",Pharmacokinetics and tissue residues of hydrochloric acid albendazole sulfoxide and its metabolites in crucian carp (Carassius auratus) after oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22227164/),[l] / [h·kg],0.49,18706,DB00518,Albendazole
,22227164,AUC,"The [Formula: see text] of ABZSO(2) was found to be 6.39 °C at 10 °C and 3.73 h at 25 °C, whereas the [Formula: see text] was 12.86 h at 10 °C and 6.56 h at 25 °C; the C(max) and T(p) of ABZSO(2) was calculated as 0.78 μg mL(-1) and 12.82 h at 10 °C, 1.03 μg mL(-1) and 7.04 h at 25 °C, respectively; the V(d)/F of ABZSO(2) were estimated to be 6.43 L kg(-1) at 10 °C and 4.61 Lkg(-1) at 25 °C; the CL(b) of ABZSO(2) were computed as 0.34 and 0.49 L/(h kg) at 10 °C and 25 °C, respectively; the AUC of ABZSO(2) were 28.86 μg mL(-1)h at 10 °C and 20.52 μg mL(-1)h at 25 °C.",Pharmacokinetics and tissue residues of hydrochloric acid albendazole sulfoxide and its metabolites in crucian carp (Carassius auratus) after oral administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22227164/),[μg] / [ml],28.86,18707,DB00518,Albendazole
,22227164,AUC,"The [Formula: see text] of ABZSO(2) was found to be 6.39 °C at 10 °C and 3.73 h at 25 °C, whereas the [Formula: see text] was 12.86 h at 10 °C and 6.56 h at 25 °C; the C(max) and T(p) of ABZSO(2) was calculated as 0.78 μg mL(-1) and 12.82 h at 10 °C, 1.03 μg mL(-1) and 7.04 h at 25 °C, respectively; the V(d)/F of ABZSO(2) were estimated to be 6.43 L kg(-1) at 10 °C and 4.61 Lkg(-1) at 25 °C; the CL(b) of ABZSO(2) were computed as 0.34 and 0.49 L/(h kg) at 10 °C and 25 °C, respectively; the AUC of ABZSO(2) were 28.86 μg mL(-1)h at 10 °C and 20.52 μg mL(-1)h at 25 °C.",Pharmacokinetics and tissue residues of hydrochloric acid albendazole sulfoxide and its metabolites in crucian carp (Carassius auratus) after oral administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22227164/),[μg] / [ml],20.52,18708,DB00518,Albendazole
,9195734,area under the plasma concentration vs time curve (AUC),The area under the plasma concentration vs time curve (AUC) values for ABZSO were higher in both artificially infected (64.0 micrograms h ml-1) and naturally infected (79.3 micrograms h ml-1) sheep as compared with non-infected animals (41.8 micrograms h ml-1).,Modified plasma and abomasal disposition of albendazole in nematode-infected sheep. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9195734/),[h·μg] / [ml],64.0,22630,DB00518,Albendazole
,9195734,area under the plasma concentration vs time curve (AUC),The area under the plasma concentration vs time curve (AUC) values for ABZSO were higher in both artificially infected (64.0 micrograms h ml-1) and naturally infected (79.3 micrograms h ml-1) sheep as compared with non-infected animals (41.8 micrograms h ml-1).,Modified plasma and abomasal disposition of albendazole in nematode-infected sheep. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9195734/),[h·μg] / [ml],79.3,22631,DB00518,Albendazole
,9195734,area under the plasma concentration vs time curve (AUC),The area under the plasma concentration vs time curve (AUC) values for ABZSO were higher in both artificially infected (64.0 micrograms h ml-1) and naturally infected (79.3 micrograms h ml-1) sheep as compared with non-infected animals (41.8 micrograms h ml-1).,Modified plasma and abomasal disposition of albendazole in nematode-infected sheep. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9195734/),[h·μg] / [ml],41.8,22632,DB00518,Albendazole
,24462508,efficacies,"The observed efficacies were 52% (LEV), 72% (ABZ), 80% (IVM) and 87% (triple combined formulation).","Evaluation of pharmacological interactions after administration of a levamisole, albendazole and ivermectin triple combination in lambs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24462508/),%,52,24392,DB00518,Albendazole
,24462508,efficacies,"The observed efficacies were 52% (LEV), 72% (ABZ), 80% (IVM) and 87% (triple combined formulation).","Evaluation of pharmacological interactions after administration of a levamisole, albendazole and ivermectin triple combination in lambs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24462508/),%,72,24393,DB00518,Albendazole
,24462508,efficacies,"The observed efficacies were 52% (LEV), 72% (ABZ), 80% (IVM) and 87% (triple combined formulation).","Evaluation of pharmacological interactions after administration of a levamisole, albendazole and ivermectin triple combination in lambs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24462508/),%,80,24394,DB00518,Albendazole
,24462508,efficacies,"The observed efficacies were 52% (LEV), 72% (ABZ), 80% (IVM) and 87% (triple combined formulation).","Evaluation of pharmacological interactions after administration of a levamisole, albendazole and ivermectin triple combination in lambs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24462508/),%,87,24395,DB00518,Albendazole
,26318978,brain concentration,"Considering that the brain concentration at 24h was 1400±160.1ng/g (ABZ-SO) and 120±35.2ng/g (CUR), the in vitro efficacy seen at a 10 fold lower concentration of the drugs strongly supports the assumption of clinical efficacy.",Intranasal microemulsion for targeted nose to brain delivery in neurocysticercosis: Role of docosahexaenoic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26318978/),[ng] / [g],1400,25386,DB00518,Albendazole
,26318978,brain concentration,"Considering that the brain concentration at 24h was 1400±160.1ng/g (ABZ-SO) and 120±35.2ng/g (CUR), the in vitro efficacy seen at a 10 fold lower concentration of the drugs strongly supports the assumption of clinical efficacy.",Intranasal microemulsion for targeted nose to brain delivery in neurocysticercosis: Role of docosahexaenoic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26318978/),[ng] / [g],120,25387,DB00518,Albendazole
>,9769065,AUC,"An extensive plasma/abomasum exchange process, with ionic-trapping in the abomasum, accounted for the higher AUC value (>200 per cent) obtained for RBZ in abomasum compared with plasma.",Ricobendazole kinetics and availability following subcutaneous administration of a novel injectable formulation to calves. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9769065/),%,200,27821,DB00518,Albendazole
,1740534,Maximum plasma levels,Maximum plasma levels for albendazole sulphoxide ranged from 0.45 to 2.96 micrograms/mL.,Clinical pharmacokinetics of albendazole in patients with brain cysticercosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1740534/),[μg] / [ml],0.45 to 2.96,31432,DB00518,Albendazole
,1740534,half-life,The half-life of albendazole sulphoxide was between 10 and 15 hours.,Clinical pharmacokinetics of albendazole in patients with brain cysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1740534/),h,10 and 15,31433,DB00518,Albendazole
,1740534,Mean residence time,Mean residence time values were from 14 to 20 hours.,Clinical pharmacokinetics of albendazole in patients with brain cysticercosis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1740534/),h,14 to 20,31434,DB00518,Albendazole
,8933305,maximum residue,"Considering that the established maximum residue limit for ovine milk is 100 micrograms/kg for ABZ plus its metabolites, our results confirmed the appropriateness of the currently prescribed withdrawal time (3 d) after the use of ABZ in lactating sheep.",Distribution of the anthelmintic drug albendazole and its major metabolites in ovine milk and milk products after a single oral dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8933305/),[μg] / [kg],100,33164,DB00518,Albendazole
,12088859,peak concentrations (C(max)),"The results demonstrated that the mean peak concentrations (C(max)) for AbzT and AbzE were 1.06+/-0.38 mg/l and 1.71+/-0.47 mg/l, respectively; the area under the concentration-time curves (AUC) were 13.24+/-4.93 mg x h/l and 21.01+/-7.54 mg x h/l, respectively.",Albendazole-soybean oil emulsion for the treatment of human cystic echinococcosis: evaluation of bioavailability and bioequivalence. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12088859/),[mg] / [l],1.06,36775,DB00518,Albendazole
,12088859,peak concentrations (C(max)),"The results demonstrated that the mean peak concentrations (C(max)) for AbzT and AbzE were 1.06+/-0.38 mg/l and 1.71+/-0.47 mg/l, respectively; the area under the concentration-time curves (AUC) were 13.24+/-4.93 mg x h/l and 21.01+/-7.54 mg x h/l, respectively.",Albendazole-soybean oil emulsion for the treatment of human cystic echinococcosis: evaluation of bioavailability and bioequivalence. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12088859/),[mg] / [l],1.71,36776,DB00518,Albendazole
,12088859,area under the concentration-time curves (AUC),"The results demonstrated that the mean peak concentrations (C(max)) for AbzT and AbzE were 1.06+/-0.38 mg/l and 1.71+/-0.47 mg/l, respectively; the area under the concentration-time curves (AUC) were 13.24+/-4.93 mg x h/l and 21.01+/-7.54 mg x h/l, respectively.",Albendazole-soybean oil emulsion for the treatment of human cystic echinococcosis: evaluation of bioavailability and bioequivalence. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12088859/),[h·mg] / [l],13.24,36777,DB00518,Albendazole
,12088859,area under the concentration-time curves (AUC),"The results demonstrated that the mean peak concentrations (C(max)) for AbzT and AbzE were 1.06+/-0.38 mg/l and 1.71+/-0.47 mg/l, respectively; the area under the concentration-time curves (AUC) were 13.24+/-4.93 mg x h/l and 21.01+/-7.54 mg x h/l, respectively.",Albendazole-soybean oil emulsion for the treatment of human cystic echinococcosis: evaluation of bioavailability and bioequivalence. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12088859/),[h·mg] / [l],21.01,36778,DB00518,Albendazole
,12088859,F(Flu),The relative bioavailability of AbzE was F(Flu)=1.59.,Albendazole-soybean oil emulsion for the treatment of human cystic echinococcosis: evaluation of bioavailability and bioequivalence. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12088859/),,1.59,36779,DB00518,Albendazole
,1433490,elimination half-life,ABZSO elimination half-life increased from 7.27 h (control treatment) to 14.57 h (NTB + MTZ oral) and to 11.39 h (NTB + MTZ i.m.).,Methimazole-mediated modulation of netobimin biotransformation in sheep: a pharmacokinetic assessment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1433490/),h,7.27,40710,DB00518,Albendazole
,1433490,elimination half-life,ABZSO elimination half-life increased from 7.27 h (control treatment) to 14.57 h (NTB + MTZ oral) and to 11.39 h (NTB + MTZ i.m.).,Methimazole-mediated modulation of netobimin biotransformation in sheep: a pharmacokinetic assessment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1433490/),h,14.57,40711,DB00518,Albendazole
,1433490,elimination half-life,ABZSO elimination half-life increased from 7.27 h (control treatment) to 14.57 h (NTB + MTZ oral) and to 11.39 h (NTB + MTZ i.m.).,Methimazole-mediated modulation of netobimin biotransformation in sheep: a pharmacokinetic assessment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1433490/),h,11.39,40712,DB00518,Albendazole
,1433490,mean residence times,"The mean residence times for ABZSO were 12.66 +/- 0.68 h (control treatment), 18.85 +/- 2.35 h (NTB + MTZ oral) and 17.02 +/- 0.90 h (NTB + MTZ i.m.).",Methimazole-mediated modulation of netobimin biotransformation in sheep: a pharmacokinetic assessment. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1433490/),h,12.66,40713,DB00518,Albendazole
,1433490,mean residence times,"The mean residence times for ABZSO were 12.66 +/- 0.68 h (control treatment), 18.85 +/- 2.35 h (NTB + MTZ oral) and 17.02 +/- 0.90 h (NTB + MTZ i.m.).",Methimazole-mediated modulation of netobimin biotransformation in sheep: a pharmacokinetic assessment. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1433490/),h,18.85,40714,DB00518,Albendazole
,1433490,mean residence times,"The mean residence times for ABZSO were 12.66 +/- 0.68 h (control treatment), 18.85 +/- 2.35 h (NTB + MTZ oral) and 17.02 +/- 0.90 h (NTB + MTZ i.m.).",Methimazole-mediated modulation of netobimin biotransformation in sheep: a pharmacokinetic assessment. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1433490/),h,17.02,40715,DB00518,Albendazole
,2359877,m,ABZ for 105 days in sheep (m = 0.06 +/- 0.032 micrograms ml-1) and 85 days in cattle (m = 0.10 +/- 0.019 micrograms ml-1).,Pharmacokinetics in sheep and cattle of albendazole administered by an intraruminal slow release capsule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2359877/),[μg] / [ml],0.06,46554,DB00518,Albendazole
,2359877,m,ABZ for 105 days in sheep (m = 0.06 +/- 0.032 micrograms ml-1) and 85 days in cattle (m = 0.10 +/- 0.019 micrograms ml-1).,Pharmacokinetics in sheep and cattle of albendazole administered by an intraruminal slow release capsule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2359877/),[μg] / [ml],0.10,46555,DB00518,Albendazole
,16772142,Maximum plasma concentrations (C(max)),"Maximum plasma concentrations (C(max)) of FBZSO (0.49microg/mL) and FBZSO(2) (0.60microg/mL) were detected at (t(max)) 5.67 and 8.00h, respectively, following administration of FBZSO.","Plasma disposition and faecal excretion of oxfendazole, fenbendazole and albendazole following oral administration to donkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16772142/),[μg] / [ml],0.49,46751,DB00518,Albendazole
,16772142,Maximum plasma concentrations (C(max)),"Maximum plasma concentrations (C(max)) of FBZSO (0.49microg/mL) and FBZSO(2) (0.60microg/mL) were detected at (t(max)) 5.67 and 8.00h, respectively, following administration of FBZSO.","Plasma disposition and faecal excretion of oxfendazole, fenbendazole and albendazole following oral administration to donkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16772142/),[μg] / [ml],0.60,46752,DB00518,Albendazole
,16772142,t(max),"Maximum plasma concentrations (C(max)) of FBZSO (0.49microg/mL) and FBZSO(2) (0.60microg/mL) were detected at (t(max)) 5.67 and 8.00h, respectively, following administration of FBZSO.","Plasma disposition and faecal excretion of oxfendazole, fenbendazole and albendazole following oral administration to donkeys. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16772142/),h,5.67,46753,DB00518,Albendazole
,16772142,t(max),"Maximum plasma concentrations (C(max)) of FBZSO (0.49microg/mL) and FBZSO(2) (0.60microg/mL) were detected at (t(max)) 5.67 and 8.00h, respectively, following administration of FBZSO.","Plasma disposition and faecal excretion of oxfendazole, fenbendazole and albendazole following oral administration to donkeys. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16772142/),h,8.00,46754,DB00518,Albendazole
,16772142,area under the curve (AUC),The area under the curve (AUC) of the sulphone metabolite (10.33microg h/mL) was significantly higher than that of the parent drug FBZSO (5.17microg h/mL).,"Plasma disposition and faecal excretion of oxfendazole, fenbendazole and albendazole following oral administration to donkeys. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16772142/),[h·μg] / [ml],10.33,46755,DB00518,Albendazole
,16772142,area under the curve (AUC),The area under the curve (AUC) of the sulphone metabolite (10.33microg h/mL) was significantly higher than that of the parent drug FBZSO (5.17microg h/mL).,"Plasma disposition and faecal excretion of oxfendazole, fenbendazole and albendazole following oral administration to donkeys. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16772142/),[h·μg] / [ml],5.17,46756,DB00518,Albendazole
,16772142,C(max),"C(max) of albendazole sulphoxide (ABZSO) (0.08g/mL) and albendazole sulphone (ABZSO(2)) (0.04microg/mL) were obtained at 5.71 and 8.00h, respectively, following ABZ administration.","Plasma disposition and faecal excretion of oxfendazole, fenbendazole and albendazole following oral administration to donkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16772142/),[g] / [ml],0.08,46757,DB00518,Albendazole
,16772142,C(max),"C(max) of albendazole sulphoxide (ABZSO) (0.08g/mL) and albendazole sulphone (ABZSO(2)) (0.04microg/mL) were obtained at 5.71 and 8.00h, respectively, following ABZ administration.","Plasma disposition and faecal excretion of oxfendazole, fenbendazole and albendazole following oral administration to donkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16772142/),[μg] / [ml],0.04,46758,DB00518,Albendazole
,16772142,AUC,The AUC of the sulphoxide metabolite (0.84microg h/mL) of ABZ was significantly higher than that of the sulphone metabolite (0.50microg h/mL).,"Plasma disposition and faecal excretion of oxfendazole, fenbendazole and albendazole following oral administration to donkeys. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16772142/),[h·μg] / [ml],0.84,46759,DB00518,Albendazole
,16772142,AUC,The AUC of the sulphoxide metabolite (0.84microg h/mL) of ABZ was significantly higher than that of the sulphone metabolite (0.50microg h/mL).,"Plasma disposition and faecal excretion of oxfendazole, fenbendazole and albendazole following oral administration to donkeys. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16772142/),[h·μg] / [ml],0.50,46760,DB00518,Albendazole
,15290687,amount excreted (Ae),"The pharmacokinetic parameters (P < 0.05) for (+)-ASOX, (-)-ASOX, and ASON metabolites are reported as means (95% CI); amount excreted (Ae) = 3.19 (1.53-4.85) vs. 0.72 (0.41-1.04) vs. 0.08 (0.03-0.13) mg; plasma concentration-time area under the curve, AUC(0-24) = 3.56 (0.93-6.18) vs. 0.60 (0.12-1.08) vs. 0.38 (0.20-0.55) microg x h/ml, and renal clearance Cl(R) = 1.20 (0.66-1.73) vs. 2.72 (0.39-5.05) vs. 0.25 (0.13-0.37) l/h.",Enantioselective renal excretion of albendazole metabolites in patients with neurocysticercosis. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15290687/),mg,3.19,50462,DB00518,Albendazole
,15290687,amount excreted (Ae),"The pharmacokinetic parameters (P < 0.05) for (+)-ASOX, (-)-ASOX, and ASON metabolites are reported as means (95% CI); amount excreted (Ae) = 3.19 (1.53-4.85) vs. 0.72 (0.41-1.04) vs. 0.08 (0.03-0.13) mg; plasma concentration-time area under the curve, AUC(0-24) = 3.56 (0.93-6.18) vs. 0.60 (0.12-1.08) vs. 0.38 (0.20-0.55) microg x h/ml, and renal clearance Cl(R) = 1.20 (0.66-1.73) vs. 2.72 (0.39-5.05) vs. 0.25 (0.13-0.37) l/h.",Enantioselective renal excretion of albendazole metabolites in patients with neurocysticercosis. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15290687/),mg,0.72,50463,DB00518,Albendazole
,15290687,amount excreted (Ae),"The pharmacokinetic parameters (P < 0.05) for (+)-ASOX, (-)-ASOX, and ASON metabolites are reported as means (95% CI); amount excreted (Ae) = 3.19 (1.53-4.85) vs. 0.72 (0.41-1.04) vs. 0.08 (0.03-0.13) mg; plasma concentration-time area under the curve, AUC(0-24) = 3.56 (0.93-6.18) vs. 0.60 (0.12-1.08) vs. 0.38 (0.20-0.55) microg x h/ml, and renal clearance Cl(R) = 1.20 (0.66-1.73) vs. 2.72 (0.39-5.05) vs. 0.25 (0.13-0.37) l/h.",Enantioselective renal excretion of albendazole metabolites in patients with neurocysticercosis. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15290687/),mg,0.08,50464,DB00518,Albendazole
,15290687,"plasma concentration-time area under the curve, AUC(0-24)","The pharmacokinetic parameters (P < 0.05) for (+)-ASOX, (-)-ASOX, and ASON metabolites are reported as means (95% CI); amount excreted (Ae) = 3.19 (1.53-4.85) vs. 0.72 (0.41-1.04) vs. 0.08 (0.03-0.13) mg; plasma concentration-time area under the curve, AUC(0-24) = 3.56 (0.93-6.18) vs. 0.60 (0.12-1.08) vs. 0.38 (0.20-0.55) microg x h/ml, and renal clearance Cl(R) = 1.20 (0.66-1.73) vs. 2.72 (0.39-5.05) vs. 0.25 (0.13-0.37) l/h.",Enantioselective renal excretion of albendazole metabolites in patients with neurocysticercosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15290687/),[h·μg] / [ml],3.56,50465,DB00518,Albendazole
,15290687,"plasma concentration-time area under the curve, AUC(0-24)","The pharmacokinetic parameters (P < 0.05) for (+)-ASOX, (-)-ASOX, and ASON metabolites are reported as means (95% CI); amount excreted (Ae) = 3.19 (1.53-4.85) vs. 0.72 (0.41-1.04) vs. 0.08 (0.03-0.13) mg; plasma concentration-time area under the curve, AUC(0-24) = 3.56 (0.93-6.18) vs. 0.60 (0.12-1.08) vs. 0.38 (0.20-0.55) microg x h/ml, and renal clearance Cl(R) = 1.20 (0.66-1.73) vs. 2.72 (0.39-5.05) vs. 0.25 (0.13-0.37) l/h.",Enantioselective renal excretion of albendazole metabolites in patients with neurocysticercosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15290687/),[h·μg] / [ml],0.60,50466,DB00518,Albendazole
,15290687,"plasma concentration-time area under the curve, AUC(0-24)","The pharmacokinetic parameters (P < 0.05) for (+)-ASOX, (-)-ASOX, and ASON metabolites are reported as means (95% CI); amount excreted (Ae) = 3.19 (1.53-4.85) vs. 0.72 (0.41-1.04) vs. 0.08 (0.03-0.13) mg; plasma concentration-time area under the curve, AUC(0-24) = 3.56 (0.93-6.18) vs. 0.60 (0.12-1.08) vs. 0.38 (0.20-0.55) microg x h/ml, and renal clearance Cl(R) = 1.20 (0.66-1.73) vs. 2.72 (0.39-5.05) vs. 0.25 (0.13-0.37) l/h.",Enantioselective renal excretion of albendazole metabolites in patients with neurocysticercosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15290687/),[h·μg] / [ml],0.38,50467,DB00518,Albendazole
,15290687,renal clearance Cl,"The pharmacokinetic parameters (P < 0.05) for (+)-ASOX, (-)-ASOX, and ASON metabolites are reported as means (95% CI); amount excreted (Ae) = 3.19 (1.53-4.85) vs. 0.72 (0.41-1.04) vs. 0.08 (0.03-0.13) mg; plasma concentration-time area under the curve, AUC(0-24) = 3.56 (0.93-6.18) vs. 0.60 (0.12-1.08) vs. 0.38 (0.20-0.55) microg x h/ml, and renal clearance Cl(R) = 1.20 (0.66-1.73) vs. 2.72 (0.39-5.05) vs. 0.25 (0.13-0.37) l/h.",Enantioselective renal excretion of albendazole metabolites in patients with neurocysticercosis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15290687/),[l] / [h],1.20,50468,DB00518,Albendazole
,15290687,renal clearance Cl,"The pharmacokinetic parameters (P < 0.05) for (+)-ASOX, (-)-ASOX, and ASON metabolites are reported as means (95% CI); amount excreted (Ae) = 3.19 (1.53-4.85) vs. 0.72 (0.41-1.04) vs. 0.08 (0.03-0.13) mg; plasma concentration-time area under the curve, AUC(0-24) = 3.56 (0.93-6.18) vs. 0.60 (0.12-1.08) vs. 0.38 (0.20-0.55) microg x h/ml, and renal clearance Cl(R) = 1.20 (0.66-1.73) vs. 2.72 (0.39-5.05) vs. 0.25 (0.13-0.37) l/h.",Enantioselective renal excretion of albendazole metabolites in patients with neurocysticercosis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15290687/),[l] / [h],2.72,50469,DB00518,Albendazole
,15290687,renal clearance Cl,"The pharmacokinetic parameters (P < 0.05) for (+)-ASOX, (-)-ASOX, and ASON metabolites are reported as means (95% CI); amount excreted (Ae) = 3.19 (1.53-4.85) vs. 0.72 (0.41-1.04) vs. 0.08 (0.03-0.13) mg; plasma concentration-time area under the curve, AUC(0-24) = 3.56 (0.93-6.18) vs. 0.60 (0.12-1.08) vs. 0.38 (0.20-0.55) microg x h/ml, and renal clearance Cl(R) = 1.20 (0.66-1.73) vs. 2.72 (0.39-5.05) vs. 0.25 (0.13-0.37) l/h.",Enantioselective renal excretion of albendazole metabolites in patients with neurocysticercosis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15290687/),[l] / [h],0.25,50470,DB00518,Albendazole
,15290687,Ae ratio,"Sulfone formation capacity, expressed as the Ae ratio ASON/ASOX + ASON, was 2.21 (1.43-2.99).",Enantioselective renal excretion of albendazole metabolites in patients with neurocysticercosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15290687/),,2.21,50471,DB00518,Albendazole
,21633966,flow rate,"The chromatographic resolution of ABZ, RBZ and IS was achieved with a mobile phase consisting of 5 m m ammonium acetate (pH 6) and acetonitrile (20:80, v/v) at a flow rate of 1 mL/min on a Chromolith RP-18e column.",Highly sensitive LC-MS/MS-ESI method for simultaneous quantitation of albendazole and ricobendazole in rat plasma and its application to a rat pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21633966/),[ml] / [min],1,63921,DB00518,Albendazole
,21633966,total chromatographic run time,"The total chromatographic run time was 3.5 min and the elution of ABZ, RBZ and IS occurred at 1.66, 1.50 and 1.59 min, respectively.",Highly sensitive LC-MS/MS-ESI method for simultaneous quantitation of albendazole and ricobendazole in rat plasma and its application to a rat pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21633966/),min,3.5,63922,DB00518,Albendazole
,33935787,bioavailability,"The bioavailability of the two formulations was very similar, although the sample size was not sufficient to demonstrate bioequivalence because the intraindividual variability of albendazole was approximately 60%.",High-Fat Breakfast Increases Bioavailability of Albendazole Compared to Low-Fat Breakfast: Single-Dose Study in Healthy Subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33935787/),%,60,68278,DB00518,Albendazole
,2315975,detection limit,The detection limit of the main metabolite ASOX was 50 nM and that of ASON was 100 nM.,Therapeutic monitoring of albendazole: a high-performance liquid chromatography method for determination of its active metabolite albendazole sulfoxide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2315975/),nM,50,76145,DB00518,Albendazole
,2315975,detection limit,The detection limit of the main metabolite ASOX was 50 nM and that of ASON was 100 nM.,Therapeutic monitoring of albendazole: a high-performance liquid chromatography method for determination of its active metabolite albendazole sulfoxide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2315975/),nM,100,76146,DB00518,Albendazole
,33527105,run time,"An Xselect CSH™ C18 HPLC column was utilized as a stationary phase, with a mobile phase consisting of 0.1% v/v trifluoracetic acid in water and acetonitrile with a run time of 20 min.",New and sensitive HPLC-UV method for concomitant quantification of a combination of antifilariasis drugs in rat plasma and organs after simultaneous oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33527105/),min,20,76307,DB00518,Albendazole
,2396793,maximal plasma drug concentration (Cmax),"Netobimin parent drug was rapidly absorbed, being detected between 0.25 and 12 hours after treatment, with maximal plasma drug concentration (Cmax) values of 2.20 +/- 1.03 micrograms/ml achieved at 0.75 +/- 0.19 hour (trisamine) and 1.37 +/- 0.59 micrograms/ml at 0.81 +/- 0.18 hour (zwitterion).",Comparison of pharmacokinetic variables for two injectable formulations of netobimin administered to calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2396793/),[μg] / [ml],2.20,77206,DB00518,Albendazole
,2396793,maximal plasma drug concentration (Cmax),"Netobimin parent drug was rapidly absorbed, being detected between 0.25 and 12 hours after treatment, with maximal plasma drug concentration (Cmax) values of 2.20 +/- 1.03 micrograms/ml achieved at 0.75 +/- 0.19 hour (trisamine) and 1.37 +/- 0.59 micrograms/ml at 0.81 +/- 0.18 hour (zwitterion).",Comparison of pharmacokinetic variables for two injectable formulations of netobimin administered to calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2396793/),[μg] / [ml],1.37,77207,DB00518,Albendazole
,2396793,area under the plasma concentration-time curve (AUC),Netobimin area under the plasma concentration-time curve (AUC) was 7.59 +/- 3.11 micrograms.h/ml (trisamine) and 6.98 +/- 1.60 micrograms.h/ml (zwitterion).,Comparison of pharmacokinetic variables for two injectable formulations of netobimin administered to calves. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2396793/),[h·μg] / [ml],7.59,77208,DB00518,Albendazole
,2396793,area under the plasma concentration-time curve (AUC),Netobimin area under the plasma concentration-time curve (AUC) was 7.59 +/- 3.11 micrograms.h/ml (trisamine) and 6.98 +/- 1.60 micrograms.h/ml (zwitterion).,Comparison of pharmacokinetic variables for two injectable formulations of netobimin administered to calves. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2396793/),[h·μg] / [ml],6.98,77209,DB00518,Albendazole
,2396793,Elimination half-life (t1/2 beta),Elimination half-life (t1/2 beta) was 2.59 +/- 0.63 hours (trisamine) and 3.57 +/- 1.45 hours (zwitterion).,Comparison of pharmacokinetic variables for two injectable formulations of netobimin administered to calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2396793/),h,2.59,77210,DB00518,Albendazole
,2396793,Elimination half-life (t1/2 beta),Elimination half-life (t1/2 beta) was 2.59 +/- 0.63 hours (trisamine) and 3.57 +/- 1.45 hours (zwitterion).,Comparison of pharmacokinetic variables for two injectable formulations of netobimin administered to calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2396793/),h,3.57,77211,DB00518,Albendazole
,2396793,Cmax,"The Cmax values were 0.48 +/- 0.16 micrograms/ml and 0.46 +/- 0.26 micrograms/ml for trisamine and zwitterion formulations, respectively, achieved at time to peak drug concentration (Tmax) values of 9.50 +/- 1.41 hours (trisamine) and 11.30 +/- 1.04 hours (zwitterion).",Comparison of pharmacokinetic variables for two injectable formulations of netobimin administered to calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2396793/),[μg] / [ml],0.48,77212,DB00518,Albendazole
,2396793,Cmax,"The Cmax values were 0.48 +/- 0.16 micrograms/ml and 0.46 +/- 0.26 micrograms/ml for trisamine and zwitterion formulations, respectively, achieved at time to peak drug concentration (Tmax) values of 9.50 +/- 1.41 hours (trisamine) and 11.30 +/- 1.04 hours (zwitterion).",Comparison of pharmacokinetic variables for two injectable formulations of netobimin administered to calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2396793/),[μg] / [ml],0.46,77213,DB00518,Albendazole
,2396793,time to peak drug concentration (Tmax),"The Cmax values were 0.48 +/- 0.16 micrograms/ml and 0.46 +/- 0.26 micrograms/ml for trisamine and zwitterion formulations, respectively, achieved at time to peak drug concentration (Tmax) values of 9.50 +/- 1.41 hours (trisamine) and 11.30 +/- 1.04 hours (zwitterion).",Comparison of pharmacokinetic variables for two injectable formulations of netobimin administered to calves. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2396793/),h,9.50,77214,DB00518,Albendazole
,2396793,time to peak drug concentration (Tmax),"The Cmax values were 0.48 +/- 0.16 micrograms/ml and 0.46 +/- 0.26 micrograms/ml for trisamine and zwitterion formulations, respectively, achieved at time to peak drug concentration (Tmax) values of 9.50 +/- 1.41 hours (trisamine) and 11.30 +/- 1.04 hours (zwitterion).",Comparison of pharmacokinetic variables for two injectable formulations of netobimin administered to calves. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2396793/),h,11.30,77215,DB00518,Albendazole
,2396793,AUC,Albendazole sulfoxide AUC was 3.86 +/- 1.04 micrograms.h/ml (trisamine) and 4.40 +/- 3.24 micrograms.h/ml (zwitterion); t1/2 beta was 3.05 +/- 0.75 hours (trisamine) and 3.90 +/- 1.44 hours (zwitterion).,Comparison of pharmacokinetic variables for two injectable formulations of netobimin administered to calves. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2396793/),[h·μg] / [ml],3.86,77216,DB00518,Albendazole
,2396793,AUC,Albendazole sulfoxide AUC was 3.86 +/- 1.04 micrograms.h/ml (trisamine) and 4.40 +/- 3.24 micrograms.h/ml (zwitterion); t1/2 beta was 3.05 +/- 0.75 hours (trisamine) and 3.90 +/- 1.44 hours (zwitterion).,Comparison of pharmacokinetic variables for two injectable formulations of netobimin administered to calves. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2396793/),[h·μg] / [ml],4.40,77217,DB00518,Albendazole
,2396793,t1/2 beta,Albendazole sulfoxide AUC was 3.86 +/- 1.04 micrograms.h/ml (trisamine) and 4.40 +/- 3.24 micrograms.h/ml (zwitterion); t1/2 beta was 3.05 +/- 0.75 hours (trisamine) and 3.90 +/- 1.44 hours (zwitterion).,Comparison of pharmacokinetic variables for two injectable formulations of netobimin administered to calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2396793/),h,3.05,77218,DB00518,Albendazole
,2396793,t1/2 beta,Albendazole sulfoxide AUC was 3.86 +/- 1.04 micrograms.h/ml (trisamine) and 4.40 +/- 3.24 micrograms.h/ml (zwitterion); t1/2 beta was 3.05 +/- 0.75 hours (trisamine) and 3.90 +/- 1.44 hours (zwitterion).,Comparison of pharmacokinetic variables for two injectable formulations of netobimin administered to calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2396793/),h,3.90,77219,DB00518,Albendazole
,19004671,flow rate,"Chromatographic separations were performed on a Chiralcel OD-R 250 mm x 4.6mm column with mobile phase methanol-1M NaClO(4) (75:25, v/v) at the flow rate 0.5 ml min(-1).",Sensitive chiral high-performance liquid chromatographic determination of anthelmintic flubendazole and its phase I metabolites in blood plasma using UV photodiode-array and fluorescence detection Application to pharmacokinetic studies in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19004671/),[ml] / [min],0.5,84634,DB00518,Albendazole
,29346367,Cmax,"ABZSO Cmax in serum was 1.20 ± 0.44 μg/mL, reached at 4.75 h post-treatment.",Assessment of serum pharmacokinetics and urinary excretion of albendazole and its metabolites in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29346367/),[μg] / [ml],1.20,88675,DB00518,Albendazole
,29346367,Cmax,"In urine, ABZSO Cmax was 3.24 ± 1.51 μg/mL reached at 6.50 h post-ABZ administration.",Assessment of serum pharmacokinetics and urinary excretion of albendazole and its metabolites in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29346367/),[μg] / [ml],3.24,88676,DB00518,Albendazole
,17004041,Maximum plasma concentrations (C(max)),"Maximum plasma concentrations (C(max)) of ABZSO (4.1 +/- 0.7 microg/ml) and ABZSO(2) (1.1 +/- 0.4 microg/ml) were detected at (t(max)) 14.7 and 23.8 h, respectively following oral administration of netobimin.",Plasma disposition and faecal excretion of netobimin metabolites and enantiospecific disposition of albendazole sulphoxide produced in ewes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17004041/),[μg] / [ml],4.1,91991,DB00518,Albendazole
,17004041,Maximum plasma concentrations (C(max)),"Maximum plasma concentrations (C(max)) of ABZSO (4.1 +/- 0.7 microg/ml) and ABZSO(2) (1.1 +/- 0.4 microg/ml) were detected at (t(max)) 14.7 and 23.8 h, respectively following oral administration of netobimin.",Plasma disposition and faecal excretion of netobimin metabolites and enantiospecific disposition of albendazole sulphoxide produced in ewes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17004041/),[μg] / [ml],1.1,91992,DB00518,Albendazole
,17004041,t(max),"Maximum plasma concentrations (C(max)) of ABZSO (4.1 +/- 0.7 microg/ml) and ABZSO(2) (1.1 +/- 0.4 microg/ml) were detected at (t(max)) 14.7 and 23.8 h, respectively following oral administration of netobimin.",Plasma disposition and faecal excretion of netobimin metabolites and enantiospecific disposition of albendazole sulphoxide produced in ewes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17004041/),h,14.7,91993,DB00518,Albendazole
,17004041,t(max),"Maximum plasma concentrations (C(max)) of ABZSO (4.1 +/- 0.7 microg/ml) and ABZSO(2) (1.1 +/- 0.4 microg/ml) were detected at (t(max)) 14.7 and 23.8 h, respectively following oral administration of netobimin.",Plasma disposition and faecal excretion of netobimin metabolites and enantiospecific disposition of albendazole sulphoxide produced in ewes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17004041/),h,23.8,91994,DB00518,Albendazole
,17004041,area under the curve (AUC),The area under the curve (AUC) of ABZSO (103.8 +/- 22.8 (microg h)/ml) was significantly higher than that ABZSO(2)(26.3 +/- 10.1 (microg h)/ml) (p < 0.01).,Plasma disposition and faecal excretion of netobimin metabolites and enantiospecific disposition of albendazole sulphoxide produced in ewes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17004041/),,103.8,91995,DB00518,Albendazole
,17004041,area under the curve (AUC),The area under the curve (AUC) of ABZSO (103.8 +/- 22.8 (microg h)/ml) was significantly higher than that ABZSO(2)(26.3 +/- 10.1 (microg h)/ml) (p < 0.01).,Plasma disposition and faecal excretion of netobimin metabolites and enantiospecific disposition of albendazole sulphoxide produced in ewes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17004041/),[h·μg] / [ml],26.3,91996,DB00518,Albendazole
,17004041,AUC,The AUC of (+)-ABZSO (87.8 +/- 20.3 (microg h)/ml) was almost 6 times larger than that of (-)-ABZSO (15.5 +/- 5.1 (microg h)/ml) (p < 0.001).,Plasma disposition and faecal excretion of netobimin metabolites and enantiospecific disposition of albendazole sulphoxide produced in ewes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17004041/),,87.8,91997,DB00518,Albendazole
,17004041,AUC,The AUC of (+)-ABZSO (87.8 +/- 20.3 (microg h)/ml) was almost 6 times larger than that of (-)-ABZSO (15.5 +/- 5.1 (microg h)/ml) (p < 0.001).,Plasma disposition and faecal excretion of netobimin metabolites and enantiospecific disposition of albendazole sulphoxide produced in ewes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17004041/),[h·μg] / [ml],15.5,91998,DB00518,Albendazole
,17004041,ratio of the faecal AUC,"Unlike in the plasma samples, the proportions of the enantiomers of ABZSO were close to racemic and the ratio of the faecal AUC of (-)-ABZSO (172.22 +/- 57.6 (microg h)/g) and (+)-ABZSO (187.19 +/- 63.4 (microg h)/g) was 0.92.",Plasma disposition and faecal excretion of netobimin metabolites and enantiospecific disposition of albendazole sulphoxide produced in ewes. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17004041/),[h·μg] / [g],172.22,91999,DB00518,Albendazole
,17004041,ratio of the faecal AUC,"Unlike in the plasma samples, the proportions of the enantiomers of ABZSO were close to racemic and the ratio of the faecal AUC of (-)-ABZSO (172.22 +/- 57.6 (microg h)/g) and (+)-ABZSO (187.19 +/- 63.4 (microg h)/g) was 0.92.",Plasma disposition and faecal excretion of netobimin metabolites and enantiospecific disposition of albendazole sulphoxide produced in ewes. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17004041/),[h·μg] / [g],187.19,92000,DB00518,Albendazole
,23529958,relative bioavailability,"Compared with the ABZ suspension groups, the relative bioavailability values of ABZ and ABZSX were 146.05 and 222.15%, respectively.",Novel albendazole-chitosan nanoparticles for intestinal absorption enhancement and hepatic targeting improvement in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23529958/),%,146.05,96016,DB00518,Albendazole
,23529958,relative bioavailability,"Compared with the ABZ suspension groups, the relative bioavailability values of ABZ and ABZSX were 146.05 and 222.15%, respectively.",Novel albendazole-chitosan nanoparticles for intestinal absorption enhancement and hepatic targeting improvement in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23529958/),%,222.15,96017,DB00518,Albendazole
,2373135,AUC,The AUC of albendazole sulphoxide was increased in the latter patients (mean 122 mumols.,Albendazole kinetics in patients with echinococcosis: delayed absorption and impaired elimination in cholestasis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2373135/),mumols,122,103686,DB00518,Albendazole
,2373135,ka,"Obstructed patients had delayed absorption, ka averaging 0.39 compared to 1.41 h-1 in non-obstructed patients.",Albendazole kinetics in patients with echinococcosis: delayed absorption and impaired elimination in cholestasis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2373135/),1/[h],0.39,103687,DB00518,Albendazole
,2373135,ka,"Obstructed patients had delayed absorption, ka averaging 0.39 compared to 1.41 h-1 in non-obstructed patients.",Albendazole kinetics in patients with echinococcosis: delayed absorption and impaired elimination in cholestasis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2373135/),1/[h],1.41,103688,DB00518,Albendazole
,2373135,"elimination rate constant, ke","The corresponding elimination rate constant, ke was also prolonged, averaging 0.041 and 0.13 h-1 in the two groups, respectively.",Albendazole kinetics in patients with echinococcosis: delayed absorption and impaired elimination in cholestasis. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2373135/),1/[h],0.041,103689,DB00518,Albendazole
,2373135,"elimination rate constant, ke","The corresponding elimination rate constant, ke was also prolonged, averaging 0.041 and 0.13 h-1 in the two groups, respectively.",Albendazole kinetics in patients with echinococcosis: delayed absorption and impaired elimination in cholestasis. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2373135/),1/[h],0.13,103690,DB00518,Albendazole
,6370482,blood half life,"Albendazole sulfoxide, one of the mains albendazole blood metabolites, was assayed by HPLC and the blood half life was calculated as 8 1/2 h.",[Pharmacokinetics and urinary metabolism of albendazole in man]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370482/),h,8 1/2,108533,DB00518,Albendazole
,10333473,AUC0-infinity,"After oral co-administration of two dosages of netobimin (7.5 and 20 mg kg-1 with fenbendazole (1.1 mg kg-1) to Merino sheep, the AUC0-infinity of albendazole sulphoxide at the lower dosage of netobimin, was significantly increased (75.5 per cent) from control value (34.43 +/- 7.91 versus 60.33 +/- 11.93 microg h ml-1).",Bioavailability of albendazole sulphoxide after netobimin administration in sheep: effects of fenbendazole coadministration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10333473/),[h·μg] / [ml],34.43,109442,DB00518,Albendazole
,10333473,AUC0-infinity,"After oral co-administration of two dosages of netobimin (7.5 and 20 mg kg-1 with fenbendazole (1.1 mg kg-1) to Merino sheep, the AUC0-infinity of albendazole sulphoxide at the lower dosage of netobimin, was significantly increased (75.5 per cent) from control value (34.43 +/- 7.91 versus 60.33 +/- 11.93 microg h ml-1).",Bioavailability of albendazole sulphoxide after netobimin administration in sheep: effects of fenbendazole coadministration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10333473/),[h·μg] / [ml],60.33,109443,DB00518,Albendazole
,10333473,MRT,The pharmacokinetic parameters MRT and T1/2 were also increased: 18.96 +/- 2.54 vs 26.44 +/- 4.69 h and 10.31 +/- 1.72 vs 22.28 +/- 6.75 h respectively.,Bioavailability of albendazole sulphoxide after netobimin administration in sheep: effects of fenbendazole coadministration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10333473/),h,18.96,109444,DB00518,Albendazole
,10333473,T1/2,The pharmacokinetic parameters MRT and T1/2 were also increased: 18.96 +/- 2.54 vs 26.44 +/- 4.69 h and 10.31 +/- 1.72 vs 22.28 +/- 6.75 h respectively.,Bioavailability of albendazole sulphoxide after netobimin administration in sheep: effects of fenbendazole coadministration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10333473/),h,26.44,109445,DB00518,Albendazole
,10333473,T1/2,The pharmacokinetic parameters MRT and T1/2 were also increased: 18.96 +/- 2.54 vs 26.44 +/- 4.69 h and 10.31 +/- 1.72 vs 22.28 +/- 6.75 h respectively.,Bioavailability of albendazole sulphoxide after netobimin administration in sheep: effects of fenbendazole coadministration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10333473/),h,10.31,109446,DB00518,Albendazole
,10333473,T1/2,The pharmacokinetic parameters MRT and T1/2 were also increased: 18.96 +/- 2.54 vs 26.44 +/- 4.69 h and 10.31 +/- 1.72 vs 22.28 +/- 6.75 h respectively.,Bioavailability of albendazole sulphoxide after netobimin administration in sheep: effects of fenbendazole coadministration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10333473/),h,22.28,109447,DB00518,Albendazole
,21395645,AUC,"The administration of ABZ did not change the kinetic disposition of (+)-(S)-PZQ (-)-(R)-4-OHPZQ or (+)-(S)-4-OHPZQ, but increased the plasma concentration of (-)-(R)-PZQ by 64.77% (AUC 0.52 vs. 0.86 µg ml(-1) h).","Albendazole-praziquantel interaction in healthy volunteers: kinetic disposition, metabolism and enantioselectivity. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395645/),[h·μg] / [ml],0.52,110918,DB00518,Albendazole
,21395645,AUC,"The administration of ABZ did not change the kinetic disposition of (+)-(S)-PZQ (-)-(R)-4-OHPZQ or (+)-(S)-4-OHPZQ, but increased the plasma concentration of (-)-(R)-PZQ by 64.77% (AUC 0.52 vs. 0.86 µg ml(-1) h).","Albendazole-praziquantel interaction in healthy volunteers: kinetic disposition, metabolism and enantioselectivity. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21395645/),[h·μg] / [ml],0.86,110919,DB00518,Albendazole
,17352262,C(max),"The C(max) of albendazole sulphoxide (ABZ-SO) resulted in a much higher plasma concentration in the oral group (41.86 microg/ml) than in the i.p. group (16.84 microg/ml, p < 0.05).",Pharmacokinetics of albendazole in New Zealand white rabbits: oral versus intraperitoneal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17352262/),[μg] / [ml],41.86,111708,DB00518,Albendazole
,17352262,C(max),"The C(max) of albendazole sulphoxide (ABZ-SO) resulted in a much higher plasma concentration in the oral group (41.86 microg/ml) than in the i.p. group (16.84 microg/ml, p < 0.05).",Pharmacokinetics of albendazole in New Zealand white rabbits: oral versus intraperitoneal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17352262/),[μg] / [ml],16.84,111709,DB00518,Albendazole
,17352262,area under the concentration over time curve,"The area under the concentration over time curve of ABZ-SO in the oral group (1010.43 microg/ml/h) was also significantly higher than that of the i.p. group (528.33 microg/ml/h, p < 0.05).",Pharmacokinetics of albendazole in New Zealand white rabbits: oral versus intraperitoneal administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17352262/),[μg] / [h·ml],1010.43,111710,DB00518,Albendazole
,17352262,area under the concentration over time curve,"The area under the concentration over time curve of ABZ-SO in the oral group (1010.43 microg/ml/h) was also significantly higher than that of the i.p. group (528.33 microg/ml/h, p < 0.05).",Pharmacokinetics of albendazole in New Zealand white rabbits: oral versus intraperitoneal administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17352262/),[μg] / [h·ml],528.33,111711,DB00518,Albendazole
,19702546,t(1/2(beta)),Tylosin was rapidly distributed and eliminated from goat's bodies with t(1/2(beta)) value of 1.25 h.,Effect of albendazole administration on pharmacokinetic aspects of tylosin in lactating goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19702546/),h,1.25,115383,DB00518,Albendazole
less,19702546,V((d)),The V((d)) was less than one litre/kg and the MRT was 1.40 h.,Effect of albendazole administration on pharmacokinetic aspects of tylosin in lactating goats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19702546/),[l] / [kg],one,115384,DB00518,Albendazole
,19702546,MRT,The V((d)) was less than one litre/kg and the MRT was 1.40 h.,Effect of albendazole administration on pharmacokinetic aspects of tylosin in lactating goats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19702546/),h,1.40,115385,DB00518,Albendazole
,19702546,MRT,Concomitant administration with albendazole decreased tylosin concentrations in serum after its i.v. injection and the MRT was 1.17 h.,Effect of albendazole administration on pharmacokinetic aspects of tylosin in lactating goats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19702546/),h,1.17,115386,DB00518,Albendazole
,19702546,systemic bioavailability (F%),"Following i.m. administration, the absorption half-life and the corresponding t(max) revealed rapid absorption rate with systemic bioavailability (F%) of 76.2 %.",Effect of albendazole administration on pharmacokinetic aspects of tylosin in lactating goats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19702546/),%,76.2,115387,DB00518,Albendazole
,19702546,bioavailability,Albendazole when given concurrently with tylosin decreased its serum concentrations due to lower bioavailability (43.25 %).,Effect of albendazole administration on pharmacokinetic aspects of tylosin in lactating goats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19702546/),%,43.25,115388,DB00518,Albendazole
,18478051,bioavailability,"The mixture model had two additional fixed parameters and identified two populations, A (55% of subjects), where there was no change in bioavailability, and B (45% of subjects), where ivermectin bioavailability was increased 37%.",The effect of azithromycin on ivermectin pharmacokinetics--a population pharmacokinetic model analysis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18478051/),%,37,116652,DB00518,Albendazole
,31787656,EC50,"Among them, benzimidazole 3 was found to be the most potent of the series (EC50 0.86 µM).","Evaluation of New Benzimidazole Derivatives as Cysticidal Agents: In Vitro, in Vivo and Docking Studies. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31787656/),μM,0.86,117881,DB00518,Albendazole
,31787656,half-life,"The pharmacokinetic study showed that the half-life and mean residence time (6.06 and 11.9 h, respectively) were long after oral administration.","Evaluation of New Benzimidazole Derivatives as Cysticidal Agents: In Vitro, in Vivo and Docking Studies. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31787656/),h,6.06,117882,DB00518,Albendazole
,31787656,mean residence time,"The pharmacokinetic study showed that the half-life and mean residence time (6.06 and 11.9 h, respectively) were long after oral administration.","Evaluation of New Benzimidazole Derivatives as Cysticidal Agents: In Vitro, in Vivo and Docking Studies. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31787656/),h,11.9,117883,DB00518,Albendazole
,11514949,Total body clearance,Total body clearance was higher for (-) RBZ (150.4 mL/h.,Comparative disposition of ricobendazole enantiomers after intravenous and subcutaneous administration of a racemic formulation to calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11514949/),[ml] / [h],150.4,119089,DB00518,Albendazole
,11514949,T1/2beta,The elimination half-life of the (-) RBZ enantiomer was shorter (T1/2beta: 2.67 h) compared with the (+) enantiomer (T1/2beta: 5.41 h).,Comparative disposition of ricobendazole enantiomers after intravenous and subcutaneous administration of a racemic formulation to calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11514949/),h,2.67,119090,DB00518,Albendazole
,11514949,T1/2beta,The elimination half-life of the (-) RBZ enantiomer was shorter (T1/2beta: 2.67 h) compared with the (+) enantiomer (T1/2beta: 5.41 h).,Comparative disposition of ricobendazole enantiomers after intravenous and subcutaneous administration of a racemic formulation to calves. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11514949/),h,5.41,119091,DB00518,Albendazole
,12093190,area under the plasma concentration-time curve (AUC),"In mothers, the area under the plasma concentration-time curve (AUC) and C(max) values of (+)-ABZSO (42.4+/-10.5 microg/mL and 1.9+/-0.4 microg/mL, respectively) were higher than those of (-)-ABZSO (15.3+/-5.1 microg/mL and 1.0+/-0.3 microg/mL).",Placental transfer of albendazole sulphoxide enantiomers in sheep. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12093190/),[μg] / [ml],42.4,123742,DB00518,Albendazole
,12093190,area under the plasma concentration-time curve (AUC),"In mothers, the area under the plasma concentration-time curve (AUC) and C(max) values of (+)-ABZSO (42.4+/-10.5 microg/mL and 1.9+/-0.4 microg/mL, respectively) were higher than those of (-)-ABZSO (15.3+/-5.1 microg/mL and 1.0+/-0.3 microg/mL).",Placental transfer of albendazole sulphoxide enantiomers in sheep. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12093190/),[μg] / [ml],15.3,123743,DB00518,Albendazole
,12093190,C(max),"In mothers, the area under the plasma concentration-time curve (AUC) and C(max) values of (+)-ABZSO (42.4+/-10.5 microg/mL and 1.9+/-0.4 microg/mL, respectively) were higher than those of (-)-ABZSO (15.3+/-5.1 microg/mL and 1.0+/-0.3 microg/mL).",Placental transfer of albendazole sulphoxide enantiomers in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12093190/),[μg] / [ml],1.9,123744,DB00518,Albendazole
,12093190,C(max),"In mothers, the area under the plasma concentration-time curve (AUC) and C(max) values of (+)-ABZSO (42.4+/-10.5 microg/mL and 1.9+/-0.4 microg/mL, respectively) were higher than those of (-)-ABZSO (15.3+/-5.1 microg/mL and 1.0+/-0.3 microg/mL).",Placental transfer of albendazole sulphoxide enantiomers in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12093190/),[μg] / [ml],1.0,123745,DB00518,Albendazole
,12093190,MRT,The MRT values were 17.0+/-1.6 h for (+)-ABZSO and 13.1+/-1.8 h for (-)-ABZSO.,Placental transfer of albendazole sulphoxide enantiomers in sheep. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12093190/),h,17.0,123746,DB00518,Albendazole
,12093190,MRT,The MRT values were 17.0+/-1.6 h for (+)-ABZSO and 13.1+/-1.8 h for (-)-ABZSO.,Placental transfer of albendazole sulphoxide enantiomers in sheep. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12093190/),h,13.1,123747,DB00518,Albendazole
,12093190,AUC ratio,"The AUC ratio between (-)-ABZSO/(+)-ABZSO in the dam was 0.36 and in the fetuses 0.64, indicating a higher impairment for the (+)-enantiomer in its placental transfer to the fetus.",Placental transfer of albendazole sulphoxide enantiomers in sheep. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12093190/),,0.36,123748,DB00518,Albendazole
,12093190,AUC ratio,"The AUC ratio between (-)-ABZSO/(+)-ABZSO in the dam was 0.36 and in the fetuses 0.64, indicating a higher impairment for the (+)-enantiomer in its placental transfer to the fetus.",Placental transfer of albendazole sulphoxide enantiomers in sheep. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12093190/),,0.64,123749,DB00518,Albendazole
,12021623,area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [h·ml],6.1,128709,DB00518,Albendazole
,12021623,area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [h·ml],2.1,128710,DB00518,Albendazole
,12021623,area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [h·ml],3.1,128711,DB00518,Albendazole
,12021623,area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [h·ml],2.4,128712,DB00518,Albendazole
,12021623,maximum plasma concentration (C(max)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [ml],0.8,128713,DB00518,Albendazole
,12021623,maximum plasma concentration (C(max)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [ml],0.3,128714,DB00518,Albendazole
,12021623,maximum plasma concentration (C(max)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [ml],0.4,128715,DB00518,Albendazole
,12021623,half-life (t1/2),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),h,8.0,128716,DB00518,Albendazole
,12021623,half-life (t1/2),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),h,3.8,128717,DB00518,Albendazole
,12021623,half-life (t1/2),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),h,4.1,128718,DB00518,Albendazole
,12021623,half-life (t1/2),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),h,4.9,128719,DB00518,Albendazole
,12021623,AUC(0-12),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [h·ml],1.8,128720,DB00518,Albendazole
,12021623,AUC(0-12),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [h·ml],0.4,128721,DB00518,Albendazole
,12021623,AUC(0-12),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [h·ml],0.6,128722,DB00518,Albendazole
,12021623,AUC(0-12),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [h·ml],0.5,128723,DB00518,Albendazole
,12021623,C(max),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [ml],0.2,128724,DB00518,Albendazole
,12021623,C(max),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [ml],0.06,128725,DB00518,Albendazole
,12021623,C(max),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),[μg] / [ml],0.1,128726,DB00518,Albendazole
,12021623,t(1/2)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),,4.3,128727,DB00518,Albendazole
,12021623,t(1/2)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),,1.9,128728,DB00518,Albendazole
,12021623,t(1/2)),"The following differences (P < 0.05) were observed between the control and the phenytoin, carbamazepine, and phenobarbital groups, respectively: (+)-ASOX area under the concentration-time curve for 0 to 12 hours after treatment (AUC(0-12)) 6.1, 2.1, 3.1, 2.4 microg/h/mL; (+)-ASOX maximum plasma concentration (C(max)) 0.8, 0.3, 0.4, 0.3 microg/mL; (+)-ASOX half-life (t1/2) 8.0, 3.8, 4.1, 4.9 h; (-)-ASOX AUC(0-12) 1.8, 0.4, 0.6, 0.5 microg/h/mL; (-)-ASOX C(max) 0.2, 0.06, 0.1, 0.1 microg/mL; (-)-ASOX (t(1/2)) 4.3, 1.9, 2.2, 2.1 h; ASON AUC(0-12) 0.5, 0.2 microg/h/mL; ASON C(max) 0.8, 0.3, 0.4, 0.3 microg/mL; ASON (t(1/2)) 8.0, 3.8, 4.1 h.",Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021623/),,2.2,128729,DB00518,Albendazole
,33202977,retention times,"GMC1 and albendazole had retention times of 1.68 and 1.66 min, respectively.","Bioanalytical Assay Development and Validation for the Pharmacokinetic Study of GMC1, a Novel FKBP52 Co-chaperone Inhibitor for Castration Resistant Prostate Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33202977/),min,1.68,130881,DB00518,Albendazole
,33202977,retention times,"GMC1 and albendazole had retention times of 1.68 and 1.66 min, respectively.","Bioanalytical Assay Development and Validation for the Pharmacokinetic Study of GMC1, a Novel FKBP52 Co-chaperone Inhibitor for Castration Resistant Prostate Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33202977/),min,1.66,130882,DB00518,Albendazole
greater,33202977,extraction recovery,"The extraction recovery values of GMC1 from rat plasma and urine were greater than 95.0 ± 2.1% and 97.6 ± 4.6%, respectively, with no significant interfering matrix effect.","Bioanalytical Assay Development and Validation for the Pharmacokinetic Study of GMC1, a Novel FKBP52 Co-chaperone Inhibitor for Castration Resistant Prostate Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33202977/),%,95.0,130883,DB00518,Albendazole
,33202977,extraction recovery,"The extraction recovery values of GMC1 from rat plasma and urine were greater than 95.0 ± 2.1% and 97.6 ± 4.6%, respectively, with no significant interfering matrix effect.","Bioanalytical Assay Development and Validation for the Pharmacokinetic Study of GMC1, a Novel FKBP52 Co-chaperone Inhibitor for Castration Resistant Prostate Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33202977/),%,97.6,130884,DB00518,Albendazole
,8359981,maximum concentration (Cmax),This was largely attributable to the disposition of ABZ sulphoxide (ABZ.SO) which had a significantly lower maximum concentration (Cmax) in goats (0.94 +/- 0.04 micrograms ml-1) than in sheep (1.41 +/- 0.24 micrograms ml-1).,Comparative pharmacokinetic behaviour of albendazole in sheep and goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8359981/),[μg] / [ml],0.94,138473,DB00518,Albendazole
,8359981,maximum concentration (Cmax),This was largely attributable to the disposition of ABZ sulphoxide (ABZ.SO) which had a significantly lower maximum concentration (Cmax) in goats (0.94 +/- 0.04 micrograms ml-1) than in sheep (1.41 +/- 0.24 micrograms ml-1).,Comparative pharmacokinetic behaviour of albendazole in sheep and goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8359981/),[μg] / [ml],1.41,138474,DB00518,Albendazole
,32062366,run time,The detection was performed on a quadrupole time-of-flight (Q-TOF) high-resolution mass spectrometer using positive electrospray ionization (ESI) source with a chromatographic run time of 6.0 min.,Pharmacokinetics and tissue distribution study of liposomal albendazole in naturally Echinococcus granulosus infected sheep by a validated UPLC-Q-TOF-MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32062366/),min,6.0,138851,DB00518,Albendazole
,32062366,m,"The detection was operated using target ions of [M + H]+ at m/z 266.096 for ABZ, m/z 282.091 for ABZSO, m/z 298.086 for ABZSO2, m/z 240.081 for ABZSO2NH2 and m/z 296.104 for IS in selective ion mode, respectively.",Pharmacokinetics and tissue distribution study of liposomal albendazole in naturally Echinococcus granulosus infected sheep by a validated UPLC-Q-TOF-MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32062366/),,240.081,138852,DB00518,Albendazole
,7436109,detection limit,"Albendazole was not detectable in plasma at any time in one sheep (detection limit, 0.02 micrograms/ml) and in the other sheep, only transiently detectable.",Pharmacokinetics of albendazole in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7436109/),[μg] / [ml],0.02,143403,DB00518,Albendazole
,7436109,peak concentrations,"Albendazole sulfoxide was detectable in plasma and in abomasal fluid at mean peak concentrations of 3.2 and 26.2 micrograms/ml, respectively, 20 hours after administration.",Pharmacokinetics of albendazole in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7436109/),[μg] / [ml],3.2,143404,DB00518,Albendazole
,7436109,peak concentrations,"Albendazole sulfoxide was detectable in plasma and in abomasal fluid at mean peak concentrations of 3.2 and 26.2 micrograms/ml, respectively, 20 hours after administration.",Pharmacokinetics of albendazole in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7436109/),[μg] / [ml],26.2,143405,DB00518,Albendazole
,12139218,maximum ABZSX concentration (Cmax),"In comparison to water, maximum ABZSX concentration (Cmax) was enhanced 6.5-fold by a fatty meal (from 0.24 +/- 0.09 mg/l to 1.55 +/- 0.30 mg/l; mean +/- SD; P < 0.001) and 3.2-fold by grapefruit juice (from 0.24 +/- 0.09 mg/l to 0.76 +/- 0.37 mg/L; P = 0.031).",Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12139218/),[mg] / [l],0.24,145754,DB00518,Albendazole
,12139218,maximum ABZSX concentration (Cmax),"In comparison to water, maximum ABZSX concentration (Cmax) was enhanced 6.5-fold by a fatty meal (from 0.24 +/- 0.09 mg/l to 1.55 +/- 0.30 mg/l; mean +/- SD; P < 0.001) and 3.2-fold by grapefruit juice (from 0.24 +/- 0.09 mg/l to 0.76 +/- 0.37 mg/L; P = 0.031).",Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12139218/),[mg] / [l],1.55,145755,DB00518,Albendazole
,12139218,maximum ABZSX concentration (Cmax),"In comparison to water, maximum ABZSX concentration (Cmax) was enhanced 6.5-fold by a fatty meal (from 0.24 +/- 0.09 mg/l to 1.55 +/- 0.30 mg/l; mean +/- SD; P < 0.001) and 3.2-fold by grapefruit juice (from 0.24 +/- 0.09 mg/l to 0.76 +/- 0.37 mg/L; P = 0.031).",Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12139218/),[mg] / [l],0.76,145756,DB00518,Albendazole
,12139218,Cmax,"When grapefruit juice was combined with cimetidine, Cmax was significantly lower than with grapefruit juice alone (0.41 +/- 0.29 mg/l and 0.76 +/- 0.37 mg/l, respectively; P = 0.022).",Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12139218/),[mg] / [l],0.41,145757,DB00518,Albendazole
,12139218,Cmax,"When grapefruit juice was combined with cimetidine, Cmax was significantly lower than with grapefruit juice alone (0.41 +/- 0.29 mg/l and 0.76 +/- 0.37 mg/l, respectively; P = 0.022).",Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12139218/),[mg] / [l],0.76,145758,DB00518,Albendazole
,12139218,Half-life (T(1/2)),Half-life (T(1/2)) was 8.8 +/- 4.2 hr and 8.2 +/- 4.3 hr after administration with water or a fatty meal (P = 1.000).,Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12139218/),h,8.8,145759,DB00518,Albendazole
,12139218,Half-life (T(1/2)),Half-life (T(1/2)) was 8.8 +/- 4.2 hr and 8.2 +/- 4.3 hr after administration with water or a fatty meal (P = 1.000).,Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12139218/),h,8.2,145760,DB00518,Albendazole
,30745388,half-life (t 1/2,"Similar half-life (t 1/2 = ∼1.5 h), time to reach the maximum concentration (t max = ∼2 h), and maximum concentration (C max = 12.5 to 26.5 ng/ml) of albendazole were observed in the four matrices.","Pharmacokinetics of Albendazole, Albendazole Sulfoxide, and Albendazole Sulfone Determined from Plasma, Blood, Dried-Blood Spots, and Mitra Samples of Hookworm-Infected Adolescents. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30745388/),h,∼1.5,147780,DB00518,Albendazole
,30745388,time to reach the maximum concentration (t max,"Similar half-life (t 1/2 = ∼1.5 h), time to reach the maximum concentration (t max = ∼2 h), and maximum concentration (C max = 12.5 to 26.5 ng/ml) of albendazole were observed in the four matrices.","Pharmacokinetics of Albendazole, Albendazole Sulfoxide, and Albendazole Sulfone Determined from Plasma, Blood, Dried-Blood Spots, and Mitra Samples of Hookworm-Infected Adolescents. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30745388/),h,∼2,147781,DB00518,Albendazole
,30745388,maximum concentration (C max,"Similar half-life (t 1/2 = ∼1.5 h), time to reach the maximum concentration (t max = ∼2 h), and maximum concentration (C max = 12.5 to 26.5 ng/ml) of albendazole were observed in the four matrices.","Pharmacokinetics of Albendazole, Albendazole Sulfoxide, and Albendazole Sulfone Determined from Plasma, Blood, Dried-Blood Spots, and Mitra Samples of Hookworm-Infected Adolescents. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30745388/),[ng] / [ml],12.5 to 26.5,147782,DB00518,Albendazole
,30745388,t 1/2,The metabolites reached C max after ∼4 h with a t 1/2 of ca. 7 to 8 h.,"Pharmacokinetics of Albendazole, Albendazole Sulfoxide, and Albendazole Sulfone Determined from Plasma, Blood, Dried-Blood Spots, and Mitra Samples of Hookworm-Infected Adolescents. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30745388/),h,7 to 8,147783,DB00518,Albendazole
,30745388,C max,"C max of albendazole sulfoxide (288 to 380 ng/ml) did not differ among the matrices, but higher C max of albendazole sulfone were obtained in the two microsampling devices (22 ng/ml) versus the wet matrices (14 ng/ml).","Pharmacokinetics of Albendazole, Albendazole Sulfoxide, and Albendazole Sulfone Determined from Plasma, Blood, Dried-Blood Spots, and Mitra Samples of Hookworm-Infected Adolescents. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30745388/),[ng] / [ml],288 to 380,147784,DB00518,Albendazole
,30745388,C max,"C max of albendazole sulfoxide (288 to 380 ng/ml) did not differ among the matrices, but higher C max of albendazole sulfone were obtained in the two microsampling devices (22 ng/ml) versus the wet matrices (14 ng/ml).","Pharmacokinetics of Albendazole, Albendazole Sulfoxide, and Albendazole Sulfone Determined from Plasma, Blood, Dried-Blood Spots, and Mitra Samples of Hookworm-Infected Adolescents. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30745388/),[ng] / [ml],22,147785,DB00518,Albendazole
,30745388,C max,"C max of albendazole sulfoxide (288 to 380 ng/ml) did not differ among the matrices, but higher C max of albendazole sulfone were obtained in the two microsampling devices (22 ng/ml) versus the wet matrices (14 ng/ml).","Pharmacokinetics of Albendazole, Albendazole Sulfoxide, and Albendazole Sulfone Determined from Plasma, Blood, Dried-Blood Spots, and Mitra Samples of Hookworm-Infected Adolescents. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30745388/),[ng] / [ml],14,147786,DB00518,Albendazole
,22533477,initial concentration,"ABZ parent compound showed an initial concentration of 16.4 ± 2.0 μg/mL, being rapidly metabolized into the ABZSO and ABZSO2 metabolites.",Disposition kinetics of albendazole and metabolites in laying hens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22533477/),[μg] / [ml],16.4,148189,DB00518,Albendazole
,22533477,maximum concentration (Cmax ),The ABZSO maximum concentration (Cmax ) (3.10 ± 0.78 μg/mL) was higher than that of ABZSO2 Cmax (0.34 ± 0.05 μg/mL).,Disposition kinetics of albendazole and metabolites in laying hens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22533477/),[μg] / [ml],3.10,148190,DB00518,Albendazole
,22533477,Cmax,The ABZSO maximum concentration (Cmax ) (3.10 ± 0.78 μg/mL) was higher than that of ABZSO2 Cmax (0.34 ± 0.05 μg/mL).,Disposition kinetics of albendazole and metabolites in laying hens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22533477/),[μg] / [ml],0.34,148191,DB00518,Albendazole
,22533477,area under the concentration vs time curve (AUC),"The area under the concentration vs time curve (AUC) for ABZSO (21.9 ± 3.6 μg·h/mL) was higher than that observed for ABZSO2 and ABZ (7.80 ± 1.02 and 12.0 ± 1.6 μg·h/mL, respectively).",Disposition kinetics of albendazole and metabolites in laying hens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22533477/),[h·μg] / [ml],21.9,148192,DB00518,Albendazole
,22533477,area under the concentration vs time curve (AUC),"The area under the concentration vs time curve (AUC) for ABZSO (21.9 ± 3.6 μg·h/mL) was higher than that observed for ABZSO2 and ABZ (7.80 ± 1.02 and 12.0 ± 1.6 μg·h/mL, respectively).",Disposition kinetics of albendazole and metabolites in laying hens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22533477/),[h·μg] / [ml],7.80,148193,DB00518,Albendazole
,22533477,area under the concentration vs time curve (AUC),"The area under the concentration vs time curve (AUC) for ABZSO (21.9 ± 3.6 μg·h/mL) was higher than that observed for ABZSO2 and ABZ (7.80 ± 1.02 and 12.0 ± 1.6 μg·h/mL, respectively).",Disposition kinetics of albendazole and metabolites in laying hens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22533477/),[h·μg] / [ml],12.0,148194,DB00518,Albendazole
,22533477,body clearance (Cl),The ABZ body clearance (Cl) was 0.88 ± 0.11 L·h/kg with an elimination half-life (T1/2el ) of 3.47 ± 0.73 h.,Disposition kinetics of albendazole and metabolites in laying hens. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22533477/),[h·l] / [kg],0.88,148195,DB00518,Albendazole
,22533477,elimination half-life (T1/2el ),The ABZ body clearance (Cl) was 0.88 ± 0.11 L·h/kg with an elimination half-life (T1/2el ) of 3.47 ± 0.73 h.,Disposition kinetics of albendazole and metabolites in laying hens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22533477/),h,3.47,148196,DB00518,Albendazole
,22533477,T1/2el,"The T1/2el for ABZSO and ABZSO2 were 6.36 ± 1.50 and 5.40 ± 1.90 h, respectively.",Disposition kinetics of albendazole and metabolites in laying hens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22533477/),h,6.36,148197,DB00518,Albendazole
,22533477,T1/2el,"The T1/2el for ABZSO and ABZSO2 were 6.36 ± 1.50 and 5.40 ± 1.90 h, respectively.",Disposition kinetics of albendazole and metabolites in laying hens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22533477/),h,5.40,148198,DB00518,Albendazole
,22533477,Cmax,"ABZ was rapidly metabolized to ABZSO (Cmax , 1.71 ± 0.62 μg/mL) and ABZSO2 (Cmax , 0.43 ± 0.04 μg/mL).",Disposition kinetics of albendazole and metabolites in laying hens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22533477/),[μg] / [ml],1.71,148199,DB00518,Albendazole
,22533477,Cmax,"ABZ was rapidly metabolized to ABZSO (Cmax , 1.71 ± 0.62 μg/mL) and ABZSO2 (Cmax , 0.43 ± 0.04 μg/mL).",Disposition kinetics of albendazole and metabolites in laying hens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22533477/),[μg] / [ml],0.43,148200,DB00518,Albendazole
,22533477,systemic exposure (AUC),"The metabolite systemic exposure (AUC) values were 18.6 ± 2.0 and 10.6 ± 0.9 μg·h/mL for ABZSO and ABZSO2 , respectively.",Disposition kinetics of albendazole and metabolites in laying hens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22533477/),[h·μg] / [ml],18.6,148201,DB00518,Albendazole
,22533477,systemic exposure (AUC),"The metabolite systemic exposure (AUC) values were 18.6 ± 2.0 and 10.6 ± 0.9 μg·h/mL for ABZSO and ABZSO2 , respectively.",Disposition kinetics of albendazole and metabolites in laying hens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22533477/),[h·μg] / [ml],10.6,148202,DB00518,Albendazole
,22533477,half-life,"The half-life values after ABZ oral were similar (5.91 ± 0.60 and 5.57 ± 1.19 h for ABZSO and ABZSO2 , respectively) to those obtained after ABZ i.v. administration.",Disposition kinetics of albendazole and metabolites in laying hens. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22533477/),h,5.91,148203,DB00518,Albendazole
,22533477,half-life,"The half-life values after ABZ oral were similar (5.91 ± 0.60 and 5.57 ± 1.19 h for ABZSO and ABZSO2 , respectively) to those obtained after ABZ i.v. administration.",Disposition kinetics of albendazole and metabolites in laying hens. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22533477/),h,5.57,148204,DB00518,Albendazole
,22533477,AUC,"AUC values of ABZSO and ABZSO2 were 61.9 and 92.4 μg·h/mL, respectively.",Disposition kinetics of albendazole and metabolites in laying hens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22533477/),[h·μg] / [ml],61.9,148205,DB00518,Albendazole
,22533477,AUC,"AUC values of ABZSO and ABZSO2 were 61.9 and 92.4 μg·h/mL, respectively.",Disposition kinetics of albendazole and metabolites in laying hens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22533477/),[h·μg] / [ml],92.4,148206,DB00518,Albendazole
,12408915,detection limit,"The assay was accurate and reproducible with a detection limit of 10 ng/ml for ABZ-SO, 2 ng/ml for ABZ-SO(2) and 4 ng/ml for ABZ-SO(2)-NH(2).",A high performance liquid chromatography method for simultaneous determination of albendazole metabolites in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12408915/),[ng] / [ml],10,148503,DB00518,Albendazole
,12408915,detection limit,"The assay was accurate and reproducible with a detection limit of 10 ng/ml for ABZ-SO, 2 ng/ml for ABZ-SO(2) and 4 ng/ml for ABZ-SO(2)-NH(2).",A high performance liquid chromatography method for simultaneous determination of albendazole metabolites in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12408915/),[ng] / [ml],2,148504,DB00518,Albendazole
,12408915,detection limit,"The assay was accurate and reproducible with a detection limit of 10 ng/ml for ABZ-SO, 2 ng/ml for ABZ-SO(2) and 4 ng/ml for ABZ-SO(2)-NH(2).",A high performance liquid chromatography method for simultaneous determination of albendazole metabolites in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12408915/),[ng] / [ml],4,148505,DB00518,Albendazole
,28344497,maximum plasma concentration,"Results: In study 1, tizoxanide reached a maximum plasma concentration of 244.42 ± 31.98 ng/mL at 0.25 h; however, in cerebrospinal fluid, this could be detected only at 0.5 h, and levels were below the quantification limit (10 ng/mL).",Effect of nitazoxanide on albendazole pharmacokinetics in cerebrospinal fluid and plasma in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28344497/),[ng] / [ml],244.42,158353,DB00518,Albendazole
,8751036,maximal plasma concentration (Cmax),The maximal plasma concentration (Cmax) of ABZSO was detected at 11.6 +/- 1.0 h and for ABZSO2 at 16.5 +/- 2.3 h.,Transplacental transport of netobimin metabolites in ewes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751036/),,11,162327,DB00518,Albendazole
,8751036,maximal plasma concentration (Cmax),The maximal plasma concentration (Cmax) of ABZSO was detected at 11.6 +/- 1.0 h and for ABZSO2 at 16.5 +/- 2.3 h.,Transplacental transport of netobimin metabolites in ewes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8751036/),h,16.5,162328,DB00518,Albendazole
,2614859,maximum concentrations (mean Cmax,"ABZ metabolism was consistent with first-pass clearance by the liver, resulting in ABZ sulphoxide (ABZ-SO) and ABZ sulphone (ABZ-SO2) being present in plasma at maximum concentrations (mean Cmax +/- SD) of 2.0 +/- 0.2 micrograms/ml and 0.4 +/- 0.1 micrograms/ml after 8 +/- 3 h and 24 +/- 5 h, respectively.",The disposition of albendazole in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614859/),[μg] / [ml],2.0,168185,DB00518,Albendazole
,2614859,maximum concentrations (mean Cmax,"ABZ metabolism was consistent with first-pass clearance by the liver, resulting in ABZ sulphoxide (ABZ-SO) and ABZ sulphone (ABZ-SO2) being present in plasma at maximum concentrations (mean Cmax +/- SD) of 2.0 +/- 0.2 micrograms/ml and 0.4 +/- 0.1 micrograms/ml after 8 +/- 3 h and 24 +/- 5 h, respectively.",The disposition of albendazole in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614859/),[μg] / [ml],0.4,168186,DB00518,Albendazole
,2614859,Cmax,"The concentration of the major biliary metabolite, unconjugated ABZ-SO, followed a similar time profile to that of ABZ-SO in plasma except that Cmax was much higher (6.2 +/- 2.2 micrograms/ml).",The disposition of albendazole in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614859/),[μg] / [ml],6.2,168187,DB00518,Albendazole
,18585256,flow rate,"The chromatographic separations of all target compounds were performed at 30 degrees C using a mobile phase composed of phosphate buffer (10 mmol L(-1); pH 7.5):acetonitrile (60:40, v/v), flow rate of 0.5 mL min(-1) and fluorescence detection at 290 nm and 320 nm, excitation and emission, respectively.",Determination of albendazole metabolites by direct injection of bovine plasma and multidimensional achiral-chiral high performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18585256/),[ml] / [min],0.5,168774,DB00518,Albendazole
,22670782,dissolution rates,"Only a 4% of total ABZ was dissolved at 5 min post-incubation, reaching dissolution rates of 32.8% (PEG 6000) and 69.4% (P 188) in SDs.",Enhanced dissolution and systemic availability of albendazole formulated as solid dispersions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22670782/),%,32.8,171666,DB00518,Albendazole
,22670782,dissolution rates,"Only a 4% of total ABZ was dissolved at 5 min post-incubation, reaching dissolution rates of 32.8% (PEG 6000) and 69.4% (P 188) in SDs.",Enhanced dissolution and systemic availability of albendazole formulated as solid dispersions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22670782/),%,69.4,171667,DB00518,Albendazole
,19840532,bioavailability,"One subpopulation comprising of 27% of the total population had a bioavailability of 28%, with the remaining subpopulation defined to have complete bioavailability.",Population pharmacokinetics of albendazole in patients with neurocysticercosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19840532/),%,28,172155,DB00518,Albendazole
,19840532,CL/F,"The CL/F and V/F for a standard 70 kg individual was determined to be 51.6 l/h and 4560 l, respectively.",Population pharmacokinetics of albendazole in patients with neurocysticercosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19840532/),[l] / [h],51.6,172156,DB00518,Albendazole
,19840532,V/F,"The CL/F and V/F for a standard 70 kg individual was determined to be 51.6 l/h and 4560 l, respectively.",Population pharmacokinetics of albendazole in patients with neurocysticercosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19840532/),l,4560,172157,DB00518,Albendazole
,2034891,ABZ,"ABZ was estimated at 3.0 in sheep, 1.5 in goats and 4.0 in cattle.","Chiral behaviour of the metabolite albendazole sulphoxide in sheep, goats and cattle. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2034891/),,3.0,173797,DB00518,Albendazole
,2034891,ABZ,"ABZ was estimated at 3.0 in sheep, 1.5 in goats and 4.0 in cattle.","Chiral behaviour of the metabolite albendazole sulphoxide in sheep, goats and cattle. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2034891/),,1.5,173798,DB00518,Albendazole
,2034891,ABZ,"ABZ was estimated at 3.0 in sheep, 1.5 in goats and 4.0 in cattle.","Chiral behaviour of the metabolite albendazole sulphoxide in sheep, goats and cattle. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2034891/),,4.0,173799,DB00518,Albendazole
>,34353029,relative bioavailability,"In in vivo pharmacokinetic studies, the AUC and relative bioavailability values of ABZ delivered by NC-loaded DMNs were found to be significantly higher than those obtained after oral administration of coarse suspension of ABZ or ABZ-NCs, as well as DMNs delivering coarse ABZ as indicated by the relative bioavailability values of >100%.",Albendazole Nanocrystal-Based Dissolving Microneedles with Improved Pharmacokinetic Performance for Enhanced Treatment of Cystic Echinococcosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34353029/),%,100,175551,DB00518,Albendazole
,24975211,retention time,The retention time was approximately 4.8min.,Liquid chromatography-mass spectrometry analysis of diethylcarbamazine in human plasma for clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24975211/),min,4.8,180933,DB00518,Albendazole
,24975211,Recovery,Recovery of DEC from plasma ranged from 84.2% to 90.1%.,Liquid chromatography-mass spectrometry analysis of diethylcarbamazine in human plasma for clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24975211/),%,84.2,180934,DB00518,Albendazole
,24975211,Recovery,Recovery of DEC from plasma ranged from 84.2% to 90.1%.,Liquid chromatography-mass spectrometry analysis of diethylcarbamazine in human plasma for clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24975211/),%,90.1,180935,DB00518,Albendazole
,14670741,flow rate,"The mobile phase consisting of acetonitrile-water-perchloric acid (70%) (30:110:0.06 (v/v/v)) was pumped at a flow rate of 0.80 ml/min on a 5 microm, reverse phase, Discovery RPamide C16 column with UV detection at 290 nm.",Albendazole sulphoxide concentrations in plasma of endemic normals from a lymphatic filariasis endemic region using liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14670741/),[ml] / [min],0.80,184547,DB00518,Albendazole
,14670741,limit of quantification,"The limit of quantification was 50 ng/ml for albendazole, 25 ng/ml for albendazole sulphoxide and 30 ng/ml for albendazole sulphone.",Albendazole sulphoxide concentrations in plasma of endemic normals from a lymphatic filariasis endemic region using liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14670741/),[ng] / [ml],50,184548,DB00518,Albendazole
,14670741,limit of quantification,"The limit of quantification was 50 ng/ml for albendazole, 25 ng/ml for albendazole sulphoxide and 30 ng/ml for albendazole sulphone.",Albendazole sulphoxide concentrations in plasma of endemic normals from a lymphatic filariasis endemic region using liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14670741/),[ng] / [ml],25,184549,DB00518,Albendazole
,14670741,limit of quantification,"The limit of quantification was 50 ng/ml for albendazole, 25 ng/ml for albendazole sulphoxide and 30 ng/ml for albendazole sulphone.",Albendazole sulphoxide concentrations in plasma of endemic normals from a lymphatic filariasis endemic region using liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14670741/),[ng] / [ml],30,184550,DB00518,Albendazole
,14670741,extraction recoveries,"The mean extraction recoveries of albendazole, albendazole sulphoxide and albendazole sulphone were 79.25, 93.03 and 88.78%, respectively.",Albendazole sulphoxide concentrations in plasma of endemic normals from a lymphatic filariasis endemic region using liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14670741/),%,79.25,184551,DB00518,Albendazole
,14670741,extraction recoveries,"The mean extraction recoveries of albendazole, albendazole sulphoxide and albendazole sulphone were 79.25, 93.03 and 88.78%, respectively.",Albendazole sulphoxide concentrations in plasma of endemic normals from a lymphatic filariasis endemic region using liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14670741/),%,93.03,184552,DB00518,Albendazole
,14670741,extraction recoveries,"The mean extraction recoveries of albendazole, albendazole sulphoxide and albendazole sulphone were 79.25, 93.03 and 88.78%, respectively.",Albendazole sulphoxide concentrations in plasma of endemic normals from a lymphatic filariasis endemic region using liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14670741/),%,88.78,184553,DB00518,Albendazole
,21294142,elimination half-lives,"The elimination half-lives for ALB, SOX and SON were 0.7 ± 0.27, 5.37 ± 6.03, 9.17 ± 5.12 h, respectively.",Application of ultra-performance columns in high-performance liquid chromatography for determination of albendazole and its metabolites in turkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21294142/),h,0.7,185476,DB00518,Albendazole
,21294142,elimination half-lives,"The elimination half-lives for ALB, SOX and SON were 0.7 ± 0.27, 5.37 ± 6.03, 9.17 ± 5.12 h, respectively.",Application of ultra-performance columns in high-performance liquid chromatography for determination of albendazole and its metabolites in turkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21294142/),h,5.37,185477,DB00518,Albendazole
,21294142,elimination half-lives,"The elimination half-lives for ALB, SOX and SON were 0.7 ± 0.27, 5.37 ± 6.03, 9.17 ± 5.12 h, respectively.",Application of ultra-performance columns in high-performance liquid chromatography for determination of albendazole and its metabolites in turkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21294142/),h,9.17,185478,DB00518,Albendazole
,33396585,flow rate,The flow rate was 1.00 mL/min and maximum absorption was measured with UV detector set at 300 nm.,HPLC Determination of Imidazoles with Variant Anti-Infective Activity in Their Dosage Forms and Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33396585/),[ml] / [min],1.00,187464,DB00518,Albendazole
,33396585,Limits of detection,"Limits of detection were reported to be 0.41, 0.13, 0.18, and 0.15 µg/mL for secnidazole, omeprazole, albendazole, and fenbendazole, respectively, showing a high degree of the method sensitivity.",HPLC Determination of Imidazoles with Variant Anti-Infective Activity in Their Dosage Forms and Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33396585/),[μg] / [ml],0.41,187465,DB00518,Albendazole
,33396585,Limits of detection,"Limits of detection were reported to be 0.41, 0.13, 0.18, and 0.15 µg/mL for secnidazole, omeprazole, albendazole, and fenbendazole, respectively, showing a high degree of the method sensitivity.",HPLC Determination of Imidazoles with Variant Anti-Infective Activity in Their Dosage Forms and Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33396585/),[μg] / [ml],0.13,187466,DB00518,Albendazole
,33396585,Limits of detection,"Limits of detection were reported to be 0.41, 0.13, 0.18, and 0.15 µg/mL for secnidazole, omeprazole, albendazole, and fenbendazole, respectively, showing a high degree of the method sensitivity.",HPLC Determination of Imidazoles with Variant Anti-Infective Activity in Their Dosage Forms and Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33396585/),[μg] / [ml],0.18,187467,DB00518,Albendazole
,33396585,Limits of detection,"Limits of detection were reported to be 0.41, 0.13, 0.18, and 0.15 µg/mL for secnidazole, omeprazole, albendazole, and fenbendazole, respectively, showing a high degree of the method sensitivity.",HPLC Determination of Imidazoles with Variant Anti-Infective Activity in Their Dosage Forms and Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33396585/),[μg] / [ml],0.15,187468,DB00518,Albendazole
,9646011,elimination half-life,Peak concentration in serum is reached after 1 to 2 hours and the elimination half-life is between 1 and 3 hours.,Pharmacokinetic optimisation of the treatment of neurocysticercosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9646011/),h,1 and 3,187764,DB00518,Albendazole
,9646011,half-life,Concentrations of ALBSO are highly variable between individuals and it has a half-life of between 6 and 15 hours.,Pharmacokinetic optimisation of the treatment of neurocysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9646011/),h,6 and 15,187765,DB00518,Albendazole
,26756920,solubility,"However, due to its low aqueous solubility (2.7 μM) and poor pharmacokinetics, ABZ is clinically limited as an anticancer agent.",Acyclic Cucurbit[n]uril-Type Molecular Container Enables Systemic Delivery of Effective Doses of Albendazole for Treatment of SK-OV-3 Xenograft Tumors. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26756920/),μM,2.7,188674,DB00518,Albendazole
,26756920,absolute bioavailability,"A pharmacokinetic study indicated that ABZ escapes the peritoneal cavity resulting in 78% absolute bioavailability, while its active intermediate metabolite, albendazole sulfoxide, achieved 43% absolute bioavailability.",Acyclic Cucurbit[n]uril-Type Molecular Container Enables Systemic Delivery of Effective Doses of Albendazole for Treatment of SK-OV-3 Xenograft Tumors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26756920/),%,78,188675,DB00518,Albendazole
,26756920,absolute bioavailability,"A pharmacokinetic study indicated that ABZ escapes the peritoneal cavity resulting in 78% absolute bioavailability, while its active intermediate metabolite, albendazole sulfoxide, achieved 43% absolute bioavailability.",Acyclic Cucurbit[n]uril-Type Molecular Container Enables Systemic Delivery of Effective Doses of Albendazole for Treatment of SK-OV-3 Xenograft Tumors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26756920/),%,43,188676,DB00518,Albendazole
,6136799,concentrations,"After a 10-14 mg/kg daily oral dose of albendazole, concentrations of 1844 +/- 904 ng/g wet tissue of albendazole-sulphoxide were found in the liver and 749 +/- 34 ng/g wet tissue in the lungs.",Albendazole as a potential treatment for human hydatidosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6136799/),[ng] / [g],1844,191817,DB00518,Albendazole
,6136799,concentrations,"After a 10-14 mg/kg daily oral dose of albendazole, concentrations of 1844 +/- 904 ng/g wet tissue of albendazole-sulphoxide were found in the liver and 749 +/- 34 ng/g wet tissue in the lungs.",Albendazole as a potential treatment for human hydatidosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6136799/),[ng] / [g],749,191818,DB00518,Albendazole
,26563727,half-life (t1/2),"A half-life (t1/2) of 8.06±0.15, 8.17±0.47, 11.04±0.73, 11.49±0.92, 12.52±1.04 and 16.9±1.18h was noted for ABZ (free drug), conventional ABZ tablet (F1), conventional ABZ matrix tablet (F2), PPI-ABZ complex, PPI-ABZ matrix tablet (F3) and Muco-PPI-ABZ matrix tablet (F4), respectively.",Lyophilized mucoadhesive-dendrimer enclosed matrix tablet for extended oral delivery of albendazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26563727/),h,8.06,194106,DB00518,Albendazole
,26563727,half-life (t1/2),"A half-life (t1/2) of 8.06±0.15, 8.17±0.47, 11.04±0.73, 11.49±0.92, 12.52±1.04 and 16.9±1.18h was noted for ABZ (free drug), conventional ABZ tablet (F1), conventional ABZ matrix tablet (F2), PPI-ABZ complex, PPI-ABZ matrix tablet (F3) and Muco-PPI-ABZ matrix tablet (F4), respectively.",Lyophilized mucoadhesive-dendrimer enclosed matrix tablet for extended oral delivery of albendazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26563727/),h,8.17,194107,DB00518,Albendazole
,26563727,half-life (t1/2),"A half-life (t1/2) of 8.06±0.15, 8.17±0.47, 11.04±0.73, 11.49±0.92, 12.52±1.04 and 16.9±1.18h was noted for ABZ (free drug), conventional ABZ tablet (F1), conventional ABZ matrix tablet (F2), PPI-ABZ complex, PPI-ABZ matrix tablet (F3) and Muco-PPI-ABZ matrix tablet (F4), respectively.",Lyophilized mucoadhesive-dendrimer enclosed matrix tablet for extended oral delivery of albendazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26563727/),h,11.04,194108,DB00518,Albendazole
,26563727,half-life (t1/2),"A half-life (t1/2) of 8.06±0.15, 8.17±0.47, 11.04±0.73, 11.49±0.92, 12.52±1.04 and 16.9±1.18h was noted for ABZ (free drug), conventional ABZ tablet (F1), conventional ABZ matrix tablet (F2), PPI-ABZ complex, PPI-ABZ matrix tablet (F3) and Muco-PPI-ABZ matrix tablet (F4), respectively.",Lyophilized mucoadhesive-dendrimer enclosed matrix tablet for extended oral delivery of albendazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26563727/),h,11.49,194109,DB00518,Albendazole
,26563727,half-life (t1/2),"A half-life (t1/2) of 8.06±0.15, 8.17±0.47, 11.04±0.73, 11.49±0.92, 12.52±1.04 and 16.9±1.18h was noted for ABZ (free drug), conventional ABZ tablet (F1), conventional ABZ matrix tablet (F2), PPI-ABZ complex, PPI-ABZ matrix tablet (F3) and Muco-PPI-ABZ matrix tablet (F4), respectively.",Lyophilized mucoadhesive-dendrimer enclosed matrix tablet for extended oral delivery of albendazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26563727/),h,12.52,194110,DB00518,Albendazole
,26563727,half-life (t1/2),"A half-life (t1/2) of 8.06±0.15, 8.17±0.47, 11.04±0.73, 11.49±0.92, 12.52±1.04 and 16.9±1.18h was noted for ABZ (free drug), conventional ABZ tablet (F1), conventional ABZ matrix tablet (F2), PPI-ABZ complex, PPI-ABZ matrix tablet (F3) and Muco-PPI-ABZ matrix tablet (F4), respectively.",Lyophilized mucoadhesive-dendrimer enclosed matrix tablet for extended oral delivery of albendazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26563727/),h,16.9,194111,DB00518,Albendazole
,26563727,Cmax,The in vivo drug release data showed that the Muco-PPI based formulations have a significantly higher Cmax (2.40±0.02μg/mL) compared with orally administered free ABZ (0.19±0.07μg/mL) as well as conventional tablet (0.20±0.05μg/mL).,Lyophilized mucoadhesive-dendrimer enclosed matrix tablet for extended oral delivery of albendazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26563727/),[μg] / [ml],2.40,194112,DB00518,Albendazole
,26563727,Cmax,The in vivo drug release data showed that the Muco-PPI based formulations have a significantly higher Cmax (2.40±0.02μg/mL) compared with orally administered free ABZ (0.19±0.07μg/mL) as well as conventional tablet (0.20±0.05μg/mL).,Lyophilized mucoadhesive-dendrimer enclosed matrix tablet for extended oral delivery of albendazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26563727/),[μg] / [ml],0.19,194113,DB00518,Albendazole
,26563727,Cmax,The in vivo drug release data showed that the Muco-PPI based formulations have a significantly higher Cmax (2.40±0.02μg/mL) compared with orally administered free ABZ (0.19±0.07μg/mL) as well as conventional tablet (0.20±0.05μg/mL).,Lyophilized mucoadhesive-dendrimer enclosed matrix tablet for extended oral delivery of albendazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26563727/),[μg] / [ml],0.20,194114,DB00518,Albendazole
,10868551,mean residence times,"The mean residence times were 23.4 and 16.1 h for (+)-ABZSO and 22.2 and 17.4 h for (-)-ABZSO for male and female animals, respectively.",Pharmacokinetic behaviour of albendazole sulphoxide enantiomers in male and female sheep. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10868551/),h,23.4,198116,DB00518,Albendazole
,10868551,mean residence times,"The mean residence times were 23.4 and 16.1 h for (+)-ABZSO and 22.2 and 17.4 h for (-)-ABZSO for male and female animals, respectively.",Pharmacokinetic behaviour of albendazole sulphoxide enantiomers in male and female sheep. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10868551/),h,16.1,198117,DB00518,Albendazole
,10868551,mean residence times,"The mean residence times were 23.4 and 16.1 h for (+)-ABZSO and 22.2 and 17.4 h for (-)-ABZSO for male and female animals, respectively.",Pharmacokinetic behaviour of albendazole sulphoxide enantiomers in male and female sheep. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10868551/),h,22.2,198118,DB00518,Albendazole
,10868551,mean residence times,"The mean residence times were 23.4 and 16.1 h for (+)-ABZSO and 22.2 and 17.4 h for (-)-ABZSO for male and female animals, respectively.",Pharmacokinetic behaviour of albendazole sulphoxide enantiomers in male and female sheep. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10868551/),h,17.4,198119,DB00518,Albendazole
,11442786,plasma AUC,The plasma AUC for (+)ABZSO (38.3 microg.,Albendazole sulphoxide enantiomeric ratios in plasma and target tissues after intravenous administration of ricobendazole to cattle. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11442786/),μg,38.3,203125,DB00518,Albendazole
,11442786,concentration ratios,"For instance, at 12 h post-treatment the (+)/(-) concentration ratios were: 12.9 (plasma), 1.62 (abomasal mucosa), 13.0 (abomasal fluid), 2.92 (intestinal mucosa), 9.87 (intestinal fluid) and 21.5 (bile).",Albendazole sulphoxide enantiomeric ratios in plasma and target tissues after intravenous administration of ricobendazole to cattle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11442786/),,12.9,203126,DB00518,Albendazole
,11442786,concentration ratios,"For instance, at 12 h post-treatment the (+)/(-) concentration ratios were: 12.9 (plasma), 1.62 (abomasal mucosa), 13.0 (abomasal fluid), 2.92 (intestinal mucosa), 9.87 (intestinal fluid) and 21.5 (bile).",Albendazole sulphoxide enantiomeric ratios in plasma and target tissues after intravenous administration of ricobendazole to cattle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11442786/),,1.62,203127,DB00518,Albendazole
,11442786,concentration ratios,"For instance, at 12 h post-treatment the (+)/(-) concentration ratios were: 12.9 (plasma), 1.62 (abomasal mucosa), 13.0 (abomasal fluid), 2.92 (intestinal mucosa), 9.87 (intestinal fluid) and 21.5 (bile).",Albendazole sulphoxide enantiomeric ratios in plasma and target tissues after intravenous administration of ricobendazole to cattle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11442786/),,13.0,203128,DB00518,Albendazole
,11442786,concentration ratios,"For instance, at 12 h post-treatment the (+)/(-) concentration ratios were: 12.9 (plasma), 1.62 (abomasal mucosa), 13.0 (abomasal fluid), 2.92 (intestinal mucosa), 9.87 (intestinal fluid) and 21.5 (bile).",Albendazole sulphoxide enantiomeric ratios in plasma and target tissues after intravenous administration of ricobendazole to cattle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11442786/),,2.92,203129,DB00518,Albendazole
,11442786,concentration ratios,"For instance, at 12 h post-treatment the (+)/(-) concentration ratios were: 12.9 (plasma), 1.62 (abomasal mucosa), 13.0 (abomasal fluid), 2.92 (intestinal mucosa), 9.87 (intestinal fluid) and 21.5 (bile).",Albendazole sulphoxide enantiomeric ratios in plasma and target tissues after intravenous administration of ricobendazole to cattle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11442786/),,9.87,203130,DB00518,Albendazole
,11442786,concentration ratios,"For instance, at 12 h post-treatment the (+)/(-) concentration ratios were: 12.9 (plasma), 1.62 (abomasal mucosa), 13.0 (abomasal fluid), 2.92 (intestinal mucosa), 9.87 (intestinal fluid) and 21.5 (bile).",Albendazole sulphoxide enantiomeric ratios in plasma and target tissues after intravenous administration of ricobendazole to cattle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11442786/),,21.5,203131,DB00518,Albendazole
,10079501,"maximum plasma concentration, Cmax","The pharmacokinetic parameters showing statistically significant differences between the (+) ASOX and (-) ASOX enantiomers are presented as respective means (95% CI) as follows: maximum plasma concentration, Cmax = 301.6 (179.7-423.5) vs 54.9 (21.9-87.9) ng.ml-1; elimination half-life, t1/2 = 5.2 (4.1-6.3) vs 3.3 (2.8-3.8) h, area under the plasma concentration-time curve, AUCss0-8 = 1719.2 (978.6-2459.8) vs 261.4 (102.9-419.8) ng.h.ml-1 and apparent clearance, Cl/fm = 5.8 (3.8-7.8) vs 54.0 (35.2-72.7) l.h-1.kg-1.",Enantioselective kinetic disposition of albendazole sulfoxide in patients with neurocysticercosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10079501/),[ng] / [ml],301.6,206888,DB00518,Albendazole
,10079501,"maximum plasma concentration, Cmax","The pharmacokinetic parameters showing statistically significant differences between the (+) ASOX and (-) ASOX enantiomers are presented as respective means (95% CI) as follows: maximum plasma concentration, Cmax = 301.6 (179.7-423.5) vs 54.9 (21.9-87.9) ng.ml-1; elimination half-life, t1/2 = 5.2 (4.1-6.3) vs 3.3 (2.8-3.8) h, area under the plasma concentration-time curve, AUCss0-8 = 1719.2 (978.6-2459.8) vs 261.4 (102.9-419.8) ng.h.ml-1 and apparent clearance, Cl/fm = 5.8 (3.8-7.8) vs 54.0 (35.2-72.7) l.h-1.kg-1.",Enantioselective kinetic disposition of albendazole sulfoxide in patients with neurocysticercosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10079501/),[ng] / [ml],54.9,206889,DB00518,Albendazole
,10079501,"elimination half-life, t1/2","The pharmacokinetic parameters showing statistically significant differences between the (+) ASOX and (-) ASOX enantiomers are presented as respective means (95% CI) as follows: maximum plasma concentration, Cmax = 301.6 (179.7-423.5) vs 54.9 (21.9-87.9) ng.ml-1; elimination half-life, t1/2 = 5.2 (4.1-6.3) vs 3.3 (2.8-3.8) h, area under the plasma concentration-time curve, AUCss0-8 = 1719.2 (978.6-2459.8) vs 261.4 (102.9-419.8) ng.h.ml-1 and apparent clearance, Cl/fm = 5.8 (3.8-7.8) vs 54.0 (35.2-72.7) l.h-1.kg-1.",Enantioselective kinetic disposition of albendazole sulfoxide in patients with neurocysticercosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10079501/),h,5.2,206890,DB00518,Albendazole
,10079501,"elimination half-life, t1/2","The pharmacokinetic parameters showing statistically significant differences between the (+) ASOX and (-) ASOX enantiomers are presented as respective means (95% CI) as follows: maximum plasma concentration, Cmax = 301.6 (179.7-423.5) vs 54.9 (21.9-87.9) ng.ml-1; elimination half-life, t1/2 = 5.2 (4.1-6.3) vs 3.3 (2.8-3.8) h, area under the plasma concentration-time curve, AUCss0-8 = 1719.2 (978.6-2459.8) vs 261.4 (102.9-419.8) ng.h.ml-1 and apparent clearance, Cl/fm = 5.8 (3.8-7.8) vs 54.0 (35.2-72.7) l.h-1.kg-1.",Enantioselective kinetic disposition of albendazole sulfoxide in patients with neurocysticercosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10079501/),h,3.3,206891,DB00518,Albendazole
,10079501,"area under the plasma concentration-time curve, AUCss0-8","The pharmacokinetic parameters showing statistically significant differences between the (+) ASOX and (-) ASOX enantiomers are presented as respective means (95% CI) as follows: maximum plasma concentration, Cmax = 301.6 (179.7-423.5) vs 54.9 (21.9-87.9) ng.ml-1; elimination half-life, t1/2 = 5.2 (4.1-6.3) vs 3.3 (2.8-3.8) h, area under the plasma concentration-time curve, AUCss0-8 = 1719.2 (978.6-2459.8) vs 261.4 (102.9-419.8) ng.h.ml-1 and apparent clearance, Cl/fm = 5.8 (3.8-7.8) vs 54.0 (35.2-72.7) l.h-1.kg-1.",Enantioselective kinetic disposition of albendazole sulfoxide in patients with neurocysticercosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10079501/),[h·ng] / [ml],1719.2,206892,DB00518,Albendazole
,10079501,"area under the plasma concentration-time curve, AUCss0-8","The pharmacokinetic parameters showing statistically significant differences between the (+) ASOX and (-) ASOX enantiomers are presented as respective means (95% CI) as follows: maximum plasma concentration, Cmax = 301.6 (179.7-423.5) vs 54.9 (21.9-87.9) ng.ml-1; elimination half-life, t1/2 = 5.2 (4.1-6.3) vs 3.3 (2.8-3.8) h, area under the plasma concentration-time curve, AUCss0-8 = 1719.2 (978.6-2459.8) vs 261.4 (102.9-419.8) ng.h.ml-1 and apparent clearance, Cl/fm = 5.8 (3.8-7.8) vs 54.0 (35.2-72.7) l.h-1.kg-1.",Enantioselective kinetic disposition of albendazole sulfoxide in patients with neurocysticercosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10079501/),[h·ng] / [ml],261.4,206893,DB00518,Albendazole
,10079501,"apparent clearance, Cl/fm","The pharmacokinetic parameters showing statistically significant differences between the (+) ASOX and (-) ASOX enantiomers are presented as respective means (95% CI) as follows: maximum plasma concentration, Cmax = 301.6 (179.7-423.5) vs 54.9 (21.9-87.9) ng.ml-1; elimination half-life, t1/2 = 5.2 (4.1-6.3) vs 3.3 (2.8-3.8) h, area under the plasma concentration-time curve, AUCss0-8 = 1719.2 (978.6-2459.8) vs 261.4 (102.9-419.8) ng.h.ml-1 and apparent clearance, Cl/fm = 5.8 (3.8-7.8) vs 54.0 (35.2-72.7) l.h-1.kg-1.",Enantioselective kinetic disposition of albendazole sulfoxide in patients with neurocysticercosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10079501/),[l] / [h·kg],5.8,206894,DB00518,Albendazole
,10079501,"apparent clearance, Cl/fm","The pharmacokinetic parameters showing statistically significant differences between the (+) ASOX and (-) ASOX enantiomers are presented as respective means (95% CI) as follows: maximum plasma concentration, Cmax = 301.6 (179.7-423.5) vs 54.9 (21.9-87.9) ng.ml-1; elimination half-life, t1/2 = 5.2 (4.1-6.3) vs 3.3 (2.8-3.8) h, area under the plasma concentration-time curve, AUCss0-8 = 1719.2 (978.6-2459.8) vs 261.4 (102.9-419.8) ng.h.ml-1 and apparent clearance, Cl/fm = 5.8 (3.8-7.8) vs 54.0 (35.2-72.7) l.h-1.kg-1.",Enantioselective kinetic disposition of albendazole sulfoxide in patients with neurocysticercosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10079501/),[l] / [h·kg],54.0,206895,DB00518,Albendazole
,10079501,AUC0-8,The mean value of 9.2 (7.6-10.9) for the AUC0-8(+)-ASOX/AUC0-8(-)-ASOX ratio demonstrated plasma accumulation of the (+) enantiomer.,Enantioselective kinetic disposition of albendazole sulfoxide in patients with neurocysticercosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10079501/),,9.2,206896,DB00518,Albendazole
,10079501,AUCss0-8 ratio,"Sulfone formation capacity, expressed by the AUCss0-8 ratio ASON/ASOX + ASON, was 8.0 (7.0-8.9).",Enantioselective kinetic disposition of albendazole sulfoxide in patients with neurocysticercosis. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10079501/),,8.0,206897,DB00518,Albendazole
,14609267,plasma AUC,"The plasma AUC values for ABZSO and ABZSO2 were 52.0 and 10.8 (microg x h)/ml, respectively.",Aspects of the pharmacokinetics of albendazole sulphoxide in sheep. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14609267/),[h·μg] / [ml],52.0,208732,DB00518,Albendazole
,14609267,plasma AUC,"The plasma AUC values for ABZSO and ABZSO2 were 52.0 and 10.8 (microg x h)/ml, respectively.",Aspects of the pharmacokinetics of albendazole sulphoxide in sheep. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14609267/),[h·μg] / [ml],10.8,208733,DB00518,Albendazole
,14609267,peak concentration,"The ABZSO2 metabolite was measurable in plasma between 10 min and 48 h after administration of ABZSO, reaching a peak concentration of 0.38 microg/ml at 7.7 h after treatment.",Aspects of the pharmacokinetics of albendazole sulphoxide in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14609267/),[μg] / [ml],0.38,208734,DB00518,Albendazole
,14609267,total body clearance,"The total body clearance was higher for the (-) than for the (+) enantiomer, the values being 270.6 and 147.75 (ml/h)/kg, respectively.",Aspects of the pharmacokinetics of albendazole sulphoxide in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14609267/),[ml] / [h)·kg],270.6,208735,DB00518,Albendazole
,14609267,total body clearance,"The total body clearance was higher for the (-) than for the (+) enantiomer, the values being 270.6 and 147.75 (ml/h)/kg, respectively.",Aspects of the pharmacokinetics of albendazole sulphoxide in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14609267/),[ml] / [h)·kg],147.75,208736,DB00518,Albendazole
,14609267,elimination half-life,"The elimination half-life of the (-) enantiomer was shorter than that of the (+) enantiomer, the values being 4.31 and 8.33 h, respectively.",Aspects of the pharmacokinetics of albendazole sulphoxide in sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14609267/),h,4.31,208737,DB00518,Albendazole
,14609267,elimination half-life,"The elimination half-life of the (-) enantiomer was shorter than that of the (+) enantiomer, the values being 4.31 and 8.33 h, respectively.",Aspects of the pharmacokinetics of albendazole sulphoxide in sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14609267/),h,8.33,208738,DB00518,Albendazole
,12954187,intestinal clearance,"The intestinal clearance of ABZSO was 0.106+/-0.010 ml/min, exhibiting a stereoselective intestinal elimination to (-)ABZSO form.",Intestinal elimination of albendazole sulfoxide: pharmacokinetic effects of inhibitors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12954187/),[ml] / [min],0.106,208940,DB00518,Albendazole
,12954187,intestinal elimination,"Oxfendazole, ampicillin and cyclosporine significantly reduced the intestinal elimination of ABZSO to 0.079+/-0.008, 0.069+/-0.009 and 0.065+/-0.012 ml/min, respectively.",Intestinal elimination of albendazole sulfoxide: pharmacokinetic effects of inhibitors. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12954187/),[ml] / [min],0.079,208941,DB00518,Albendazole
,12954187,intestinal elimination,"Oxfendazole, ampicillin and cyclosporine significantly reduced the intestinal elimination of ABZSO to 0.079+/-0.008, 0.069+/-0.009 and 0.065+/-0.012 ml/min, respectively.",Intestinal elimination of albendazole sulfoxide: pharmacokinetic effects of inhibitors. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12954187/),[ml] / [min],0.069,208942,DB00518,Albendazole
,12954187,intestinal elimination,"Oxfendazole, ampicillin and cyclosporine significantly reduced the intestinal elimination of ABZSO to 0.079+/-0.008, 0.069+/-0.009 and 0.065+/-0.012 ml/min, respectively.",Intestinal elimination of albendazole sulfoxide: pharmacokinetic effects of inhibitors. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12954187/),[ml] / [min],0.065,208943,DB00518,Albendazole
,9637222,Tmax,"When ABZ was given at a single dose of 50 mg/kg followed by MTZ at 3 mg/kg, a cumulative effect was observed in the ABZS-MT plasma levels with pharmacokinetic parameters (Tmax = 24 h, Cmax= 30.88 microg/ml and AUC = 1120.80 microg h/ml) significantly ( p < 0.01) higher than those following administration of ABZ alone (Tmax = 3 h, Cmax = 11.00 microg/ml and AUC = 268.03 microg h/ml).",Methimazole-mediated enhancement of albendazole oral bioavailability and anthelmintic effects against parenteral stages of Trichinella spiralis in mice: the influence of the dose-regime. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9637222/),h,24,211721,DB00518,Albendazole
,9637222,Cmax,"When ABZ was given at a single dose of 50 mg/kg followed by MTZ at 3 mg/kg, a cumulative effect was observed in the ABZS-MT plasma levels with pharmacokinetic parameters (Tmax = 24 h, Cmax= 30.88 microg/ml and AUC = 1120.80 microg h/ml) significantly ( p < 0.01) higher than those following administration of ABZ alone (Tmax = 3 h, Cmax = 11.00 microg/ml and AUC = 268.03 microg h/ml).",Methimazole-mediated enhancement of albendazole oral bioavailability and anthelmintic effects against parenteral stages of Trichinella spiralis in mice: the influence of the dose-regime. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9637222/),[μg] / [ml],30.88,211722,DB00518,Albendazole
,9637222,AUC,"When ABZ was given at a single dose of 50 mg/kg followed by MTZ at 3 mg/kg, a cumulative effect was observed in the ABZS-MT plasma levels with pharmacokinetic parameters (Tmax = 24 h, Cmax= 30.88 microg/ml and AUC = 1120.80 microg h/ml) significantly ( p < 0.01) higher than those following administration of ABZ alone (Tmax = 3 h, Cmax = 11.00 microg/ml and AUC = 268.03 microg h/ml).",Methimazole-mediated enhancement of albendazole oral bioavailability and anthelmintic effects against parenteral stages of Trichinella spiralis in mice: the influence of the dose-regime. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9637222/),[h·μg] / [ml],1120.80,211723,DB00518,Albendazole
,9637222,Tmax,"When ABZ was given at a single dose of 50 mg/kg followed by MTZ at 3 mg/kg, a cumulative effect was observed in the ABZS-MT plasma levels with pharmacokinetic parameters (Tmax = 24 h, Cmax= 30.88 microg/ml and AUC = 1120.80 microg h/ml) significantly ( p < 0.01) higher than those following administration of ABZ alone (Tmax = 3 h, Cmax = 11.00 microg/ml and AUC = 268.03 microg h/ml).",Methimazole-mediated enhancement of albendazole oral bioavailability and anthelmintic effects against parenteral stages of Trichinella spiralis in mice: the influence of the dose-regime. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9637222/),h,3,211724,DB00518,Albendazole
,9637222,Cmax,"When ABZ was given at a single dose of 50 mg/kg followed by MTZ at 3 mg/kg, a cumulative effect was observed in the ABZS-MT plasma levels with pharmacokinetic parameters (Tmax = 24 h, Cmax= 30.88 microg/ml and AUC = 1120.80 microg h/ml) significantly ( p < 0.01) higher than those following administration of ABZ alone (Tmax = 3 h, Cmax = 11.00 microg/ml and AUC = 268.03 microg h/ml).",Methimazole-mediated enhancement of albendazole oral bioavailability and anthelmintic effects against parenteral stages of Trichinella spiralis in mice: the influence of the dose-regime. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9637222/),[μg] / [ml],11.00,211725,DB00518,Albendazole
,9637222,AUC,"When ABZ was given at a single dose of 50 mg/kg followed by MTZ at 3 mg/kg, a cumulative effect was observed in the ABZS-MT plasma levels with pharmacokinetic parameters (Tmax = 24 h, Cmax= 30.88 microg/ml and AUC = 1120.80 microg h/ml) significantly ( p < 0.01) higher than those following administration of ABZ alone (Tmax = 3 h, Cmax = 11.00 microg/ml and AUC = 268.03 microg h/ml).",Methimazole-mediated enhancement of albendazole oral bioavailability and anthelmintic effects against parenteral stages of Trichinella spiralis in mice: the influence of the dose-regime. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9637222/),[h·μg] / [ml],268.03,211726,DB00518,Albendazole
,9637222,Cmax,"This cumulative effect was absent following administration of ABZ at 100 mg/kg where, after reaching a maximum (Cmax = 27.23 microg/ml) at 3 h post-administration (Tmax), the ABZS-MTplasma levels felt down quickly to values under those obtained after administration of ABZ at the same dose, but alone (AUC = 362.15 microg h/ml vs. 340.15 microg h/ml, respectively).",Methimazole-mediated enhancement of albendazole oral bioavailability and anthelmintic effects against parenteral stages of Trichinella spiralis in mice: the influence of the dose-regime. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9637222/),[μg] / [ml],27.23,211727,DB00518,Albendazole
,9637222,AUC,"This cumulative effect was absent following administration of ABZ at 100 mg/kg where, after reaching a maximum (Cmax = 27.23 microg/ml) at 3 h post-administration (Tmax), the ABZS-MTplasma levels felt down quickly to values under those obtained after administration of ABZ at the same dose, but alone (AUC = 362.15 microg h/ml vs. 340.15 microg h/ml, respectively).",Methimazole-mediated enhancement of albendazole oral bioavailability and anthelmintic effects against parenteral stages of Trichinella spiralis in mice: the influence of the dose-regime. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9637222/),[h·μg] / [ml],362.15,211728,DB00518,Albendazole
,9637222,AUC,"This cumulative effect was absent following administration of ABZ at 100 mg/kg where, after reaching a maximum (Cmax = 27.23 microg/ml) at 3 h post-administration (Tmax), the ABZS-MTplasma levels felt down quickly to values under those obtained after administration of ABZ at the same dose, but alone (AUC = 362.15 microg h/ml vs. 340.15 microg h/ml, respectively).",Methimazole-mediated enhancement of albendazole oral bioavailability and anthelmintic effects against parenteral stages of Trichinella spiralis in mice: the influence of the dose-regime. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9637222/),[h·μg] / [ml],340.15,211729,DB00518,Albendazole
,11728018,AUC,"Total drug availability in A. suum, expressed as area under the concentration versus time curve (AUC) over 180 min of incubation, was significantly greater (P<0.05) for ABZ parent drug (AUC = 4.19 +/- 0.59 microg x h xg(-1)) compared with the more polar ABZSO metabolite (AUC = 0.25 +/- 0.01 micro x h x g(-1)).",Ex vivo diffusion of albendazole and its sulfoxide metabolite into ascaris suum and Fasciola hepatica. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11728018/),[h·μg] / [g],4.19,215009,DB00518,Albendazole
,11728018,AUC,"Total drug availability in A. suum, expressed as area under the concentration versus time curve (AUC) over 180 min of incubation, was significantly greater (P<0.05) for ABZ parent drug (AUC = 4.19 +/- 0.59 microg x h xg(-1)) compared with the more polar ABZSO metabolite (AUC = 0.25 +/- 0.01 micro x h x g(-1)).",Ex vivo diffusion of albendazole and its sulfoxide metabolite into ascaris suum and Fasciola hepatica. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11728018/),[μh] / [g],0.25,215010,DB00518,Albendazole
,11728018,AUC,"Similar results were observed after the incubation of both molecules with F. hepatica, where the AUC values obtained were 10.6 +/- 0.28 microg x h x g(-1) and 2.04 +/- 0.33 microg x h x g(-1) for ABZ and ABZSO, respectively.",Ex vivo diffusion of albendazole and its sulfoxide metabolite into ascaris suum and Fasciola hepatica. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11728018/),[h·μg] / [g],10.6,215011,DB00518,Albendazole
,11728018,AUC,"Similar results were observed after the incubation of both molecules with F. hepatica, where the AUC values obtained were 10.6 +/- 0.28 microg x h x g(-1) and 2.04 +/- 0.33 microg x h x g(-1) for ABZ and ABZSO, respectively.",Ex vivo diffusion of albendazole and its sulfoxide metabolite into ascaris suum and Fasciola hepatica. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11728018/),[h·μg] / [g],2.04,215012,DB00518,Albendazole
greater,15193727,Recoveries,"Recoveries of ABZ and ABZ-SO were greater than 77 and 53%, respectively, over the calibration curve range.",Simultaneous determination of albendazole and its major active metabolite in human plasma using a sensitive and specific liquid chromatographic-tandem mass spectrometric method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15193727/),%,77,216623,DB00518,Albendazole
greater,15193727,Recoveries,"Recoveries of ABZ and ABZ-SO were greater than 77 and 53%, respectively, over the calibration curve range.",Simultaneous determination of albendazole and its major active metabolite in human plasma using a sensitive and specific liquid chromatographic-tandem mass spectrometric method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15193727/),%,53,216624,DB00518,Albendazole
more,12450544,recoveries,"The method was linear up to 2500 and 250 ng/ml for ASOX and ASON, respectively, with mean recoveries of more than 85%.",Simultaneous liquid chromatography-tandem mass spectrometric determination of albendazole sulfoxide and albendazole sulfone in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12450544/),%,85,220270,DB00518,Albendazole
,12841935,inhibition constant (K(i)),The lower inhibition constant (K(i)) value observed in the intestinal incubations (9.4 +/- 1.0 microM) compared with the hepatic counterparts (23.3 +/- 15.8 microM) pointed to a greater affinity of the enzymatic systems in the intestine.,Effect of clotrimazole on microsomal metabolism and pharmacokinetics of albendazole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12841935/),μM,9.4,223110,DB00518,Albendazole
,12841935,inhibition constant (K(i)),The lower inhibition constant (K(i)) value observed in the intestinal incubations (9.4 +/- 1.0 microM) compared with the hepatic counterparts (23.3 +/- 15.8 microM) pointed to a greater affinity of the enzymatic systems in the intestine.,Effect of clotrimazole on microsomal metabolism and pharmacokinetics of albendazole. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12841935/),μM,23.3,223111,DB00518,Albendazole
,21930885,area under the concentration-versus-time curve [AUC],FLBZ was detected in plasma (area under the concentration-versus-time curve [AUC] = 1.8 μg · h/ml) and cysts (AUC = 0.3 μg · h/g) collected from treated infected animals.,"Comparative performances of flubendazole and albendazole in cystic echinococcosis: ex vivo activity, plasma/cyst disposition, and efficacy in infected mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21930885/),[h·μg] / [ml],1.8,225906,DB00518,Albendazole
,21930885,AUC,FLBZ was detected in plasma (area under the concentration-versus-time curve [AUC] = 1.8 μg · h/ml) and cysts (AUC = 0.3 μg · h/g) collected from treated infected animals.,"Comparative performances of flubendazole and albendazole in cystic echinococcosis: ex vivo activity, plasma/cyst disposition, and efficacy in infected mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21930885/),[h·μg] / [g],0.3,225907,DB00518,Albendazole
,21930885,AUC,"Conversely, ABZSO was the only active molecule measured in plasma (AUC = 4.4 μg·h/ml) and cysts (AUC = 1.5 μg·h/g) after ABZ treatment.","Comparative performances of flubendazole and albendazole in cystic echinococcosis: ex vivo activity, plasma/cyst disposition, and efficacy in infected mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21930885/),[h·μg] / [ml],4.4,225908,DB00518,Albendazole
,21930885,AUC,"Conversely, ABZSO was the only active molecule measured in plasma (AUC = 4.4 μg·h/ml) and cysts (AUC = 1.5 μg·h/g) after ABZ treatment.","Comparative performances of flubendazole and albendazole in cystic echinococcosis: ex vivo activity, plasma/cyst disposition, and efficacy in infected mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21930885/),[h·μg] / [g],1.5,225909,DB00518,Albendazole
,17169522,flow rate,"The partial HPLC resolution of drug and metabolites was obtained using a cyanopropyl column and a mobile phase consisting of methanol:water (3:7, v/v) plus 0.5% of acetic acid, at a flow rate of 1.0 mL/min.","Simultaneous determination of albendazole metabolites, praziquantel and its metabolite in plasma by high-performance liquid chromatography-electrospray mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17169522/),[ml] / [min],1.0,227676,DB00518,Albendazole
,19022462,Maximum plasma concentration,"Maximum plasma concentration of ABZSO (0.53+/-0.14microg/ml) and ABZSO(2) (0.36+/-0.09microg/ml) were observed at (t(max)) 10.50 and 19.50h, respectively following administration of NTB.","Pharmacological assessment of netobimin as a potential anthelmintic for use in horses: plasma disposition, faecal excretion and efficacy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19022462/),[μg] / [ml],0.53,228812,DB00518,Albendazole
,19022462,Maximum plasma concentration,"Maximum plasma concentration of ABZSO (0.53+/-0.14microg/ml) and ABZSO(2) (0.36+/-0.09microg/ml) were observed at (t(max)) 10.50 and 19.50h, respectively following administration of NTB.","Pharmacological assessment of netobimin as a potential anthelmintic for use in horses: plasma disposition, faecal excretion and efficacy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19022462/),[μg] / [ml],0.36,228813,DB00518,Albendazole
,19022462,t(max),"Maximum plasma concentration of ABZSO (0.53+/-0.14microg/ml) and ABZSO(2) (0.36+/-0.09microg/ml) were observed at (t(max)) 10.50 and 19.50h, respectively following administration of NTB.","Pharmacological assessment of netobimin as a potential anthelmintic for use in horses: plasma disposition, faecal excretion and efficacy. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19022462/),h,10.50,228814,DB00518,Albendazole
,19022462,t(max),"Maximum plasma concentration of ABZSO (0.53+/-0.14microg/ml) and ABZSO(2) (0.36+/-0.09microg/ml) were observed at (t(max)) 10.50 and 19.50h, respectively following administration of NTB.","Pharmacological assessment of netobimin as a potential anthelmintic for use in horses: plasma disposition, faecal excretion and efficacy. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19022462/),h,19.50,228815,DB00518,Albendazole
,8583539,Half-life,"Half-life of CEF, SMM, SQ, OLA, PEN, ALB, and two metabolites of ALB (sulfoxide and sulfone) in various tissues ranged 0.6-1.4, 4.7-9.0, 4.5-18.9, 1.8-3.1, 0.9-3.0, 3.4-9.6, 5.0-16.1 and 7.4-12.2 h.",Comparative plasma and tissue pharmacokinetics and drug residue profiles of different chemotherapeutants in fowls and rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583539/),h,0.6-1.4,231903,DB00518,Albendazole
,8583539,Half-life,"Half-life of CEF, SMM, SQ, OLA, PEN, ALB, and two metabolites of ALB (sulfoxide and sulfone) in various tissues ranged 0.6-1.4, 4.7-9.0, 4.5-18.9, 1.8-3.1, 0.9-3.0, 3.4-9.6, 5.0-16.1 and 7.4-12.2 h.",Comparative plasma and tissue pharmacokinetics and drug residue profiles of different chemotherapeutants in fowls and rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583539/),h,4.7-9.0,231904,DB00518,Albendazole
,8583539,Half-life,"Half-life of CEF, SMM, SQ, OLA, PEN, ALB, and two metabolites of ALB (sulfoxide and sulfone) in various tissues ranged 0.6-1.4, 4.7-9.0, 4.5-18.9, 1.8-3.1, 0.9-3.0, 3.4-9.6, 5.0-16.1 and 7.4-12.2 h.",Comparative plasma and tissue pharmacokinetics and drug residue profiles of different chemotherapeutants in fowls and rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583539/),h,4.5-18.9,231905,DB00518,Albendazole
,8583539,Half-life,"Half-life of CEF, SMM, SQ, OLA, PEN, ALB, and two metabolites of ALB (sulfoxide and sulfone) in various tissues ranged 0.6-1.4, 4.7-9.0, 4.5-18.9, 1.8-3.1, 0.9-3.0, 3.4-9.6, 5.0-16.1 and 7.4-12.2 h.",Comparative plasma and tissue pharmacokinetics and drug residue profiles of different chemotherapeutants in fowls and rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583539/),h,1.8-3.1,231906,DB00518,Albendazole
,8583539,Half-life,"Half-life of CEF, SMM, SQ, OLA, PEN, ALB, and two metabolites of ALB (sulfoxide and sulfone) in various tissues ranged 0.6-1.4, 4.7-9.0, 4.5-18.9, 1.8-3.1, 0.9-3.0, 3.4-9.6, 5.0-16.1 and 7.4-12.2 h.",Comparative plasma and tissue pharmacokinetics and drug residue profiles of different chemotherapeutants in fowls and rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583539/),h,0.9-3.0,231907,DB00518,Albendazole
,8583539,Half-life,"Half-life of CEF, SMM, SQ, OLA, PEN, ALB, and two metabolites of ALB (sulfoxide and sulfone) in various tissues ranged 0.6-1.4, 4.7-9.0, 4.5-18.9, 1.8-3.1, 0.9-3.0, 3.4-9.6, 5.0-16.1 and 7.4-12.2 h.",Comparative plasma and tissue pharmacokinetics and drug residue profiles of different chemotherapeutants in fowls and rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583539/),h,3.4-9.6,231908,DB00518,Albendazole
,8583539,Half-life,"Half-life of CEF, SMM, SQ, OLA, PEN, ALB, and two metabolites of ALB (sulfoxide and sulfone) in various tissues ranged 0.6-1.4, 4.7-9.0, 4.5-18.9, 1.8-3.1, 0.9-3.0, 3.4-9.6, 5.0-16.1 and 7.4-12.2 h.",Comparative plasma and tissue pharmacokinetics and drug residue profiles of different chemotherapeutants in fowls and rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583539/),h,5.0-16.1,231909,DB00518,Albendazole
,8583539,Half-life,"Half-life of CEF, SMM, SQ, OLA, PEN, ALB, and two metabolites of ALB (sulfoxide and sulfone) in various tissues ranged 0.6-1.4, 4.7-9.0, 4.5-18.9, 1.8-3.1, 0.9-3.0, 3.4-9.6, 5.0-16.1 and 7.4-12.2 h.",Comparative plasma and tissue pharmacokinetics and drug residue profiles of different chemotherapeutants in fowls and rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583539/),h,7.4-12.2,231910,DB00518,Albendazole
,24008168,flow rate,"The mobile phase consisting of water with 1% acetic acid (40%, A) and MeOH (60%, B), was used at a flow rate of 1 mL/min.",A simple assay for the simultaneous determination of human plasma albendazole and albendazole sulfoxide levels by high performance liquid chromatography in tandem mass spectrometry with solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24008168/),[ml] / [min],1,235510,DB00518,Albendazole
,1550912,AUC,The presence of MTZ did increase significantly the ABZ AUC (138 per cent) and mean residence time (MRT) (86 per cent).,Methimazole increases the plasma concentrations of the albendazole metabolites of netobimin in sheep. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1550912/),%,138,241252,DB00518,Albendazole
,1550912,mean residence time (MRT),The presence of MTZ did increase significantly the ABZ AUC (138 per cent) and mean residence time (MRT) (86 per cent).,Methimazole increases the plasma concentrations of the albendazole metabolites of netobimin in sheep. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1550912/),%,86,241253,DB00518,Albendazole
,1550912,elimination half-life (t1/2 beta),Concomitant treatment with MTZ resulted in a notably higher ABZSO plasma profile with significantly longer elimination half-life (t1/2 beta) (390 per cent) and MRT (252 per cent) and with significantly higher AUC (95 per cent).,Methimazole increases the plasma concentrations of the albendazole metabolites of netobimin in sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1550912/),%,390,241254,DB00518,Albendazole
,1550912,MRT,Concomitant treatment with MTZ resulted in a notably higher ABZSO plasma profile with significantly longer elimination half-life (t1/2 beta) (390 per cent) and MRT (252 per cent) and with significantly higher AUC (95 per cent).,Methimazole increases the plasma concentrations of the albendazole metabolites of netobimin in sheep. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1550912/),%,252,241255,DB00518,Albendazole
,1550912,AUC,Concomitant treatment with MTZ resulted in a notably higher ABZSO plasma profile with significantly longer elimination half-life (t1/2 beta) (390 per cent) and MRT (252 per cent) and with significantly higher AUC (95 per cent).,Methimazole increases the plasma concentrations of the albendazole metabolites of netobimin in sheep. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1550912/),%,95,241256,DB00518,Albendazole
,2979257,half life,"However, in this second group, pretreatment with cimetidine (400 mg t.d.s. for 5 days) significantly increased theophylline half life from 7.7 to 9.8 +/- 1.5 h (P less than 0.001) and reduced its clearance from 0.8 to 0.60 +/- 0.1 ml min-1 kg-1 (P less than 0.005).","Theophylline disposition--effects of cimetidine, mebendazole and albendazole. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979257/),h,7.7,245443,DB00518,Albendazole
,2979257,half life,"However, in this second group, pretreatment with cimetidine (400 mg t.d.s. for 5 days) significantly increased theophylline half life from 7.7 to 9.8 +/- 1.5 h (P less than 0.001) and reduced its clearance from 0.8 to 0.60 +/- 0.1 ml min-1 kg-1 (P less than 0.005).","Theophylline disposition--effects of cimetidine, mebendazole and albendazole. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979257/),h,9.8,245444,DB00518,Albendazole
,2979257,clearance,"However, in this second group, pretreatment with cimetidine (400 mg t.d.s. for 5 days) significantly increased theophylline half life from 7.7 to 9.8 +/- 1.5 h (P less than 0.001) and reduced its clearance from 0.8 to 0.60 +/- 0.1 ml min-1 kg-1 (P less than 0.005).","Theophylline disposition--effects of cimetidine, mebendazole and albendazole. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979257/),[ml] / [kg·min],0.8,245445,DB00518,Albendazole
,2979257,clearance,"However, in this second group, pretreatment with cimetidine (400 mg t.d.s. for 5 days) significantly increased theophylline half life from 7.7 to 9.8 +/- 1.5 h (P less than 0.001) and reduced its clearance from 0.8 to 0.60 +/- 0.1 ml min-1 kg-1 (P less than 0.005).","Theophylline disposition--effects of cimetidine, mebendazole and albendazole. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979257/),[ml] / [kg·min],0.60,245446,DB00518,Albendazole
,2038091,Cmax,"ABZSO was detected from 0.5-0.75 h up to 32 h post-administration, with a Cmax for the zwitterion suspension of 1.21 +/- 0.13 micrograms/ml and AUC of 18.55 +/- 1.45 micrograms.h/ml, respectively, which were significantly higher (P less than 0.01) than the Cmax (0.67 +/- 0.12 micrograms/ml) and AUC (8.57 +/- 0.91 micrograms.h/ml) for the trisamine solution.",Pharmacokinetic profiles of netobimin metabolites after oral administration of zwitterion and trisamine formulations of netobimin to cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038091/),[μg] / [ml],1.21,248557,DB00518,Albendazole
,2038091,AUC,"ABZSO was detected from 0.5-0.75 h up to 32 h post-administration, with a Cmax for the zwitterion suspension of 1.21 +/- 0.13 micrograms/ml and AUC of 18.55 +/- 1.45 micrograms.h/ml, respectively, which were significantly higher (P less than 0.01) than the Cmax (0.67 +/- 0.12 micrograms/ml) and AUC (8.57 +/- 0.91 micrograms.h/ml) for the trisamine solution.",Pharmacokinetic profiles of netobimin metabolites after oral administration of zwitterion and trisamine formulations of netobimin to cattle. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038091/),[h·μg] / [ml],18.55,248558,DB00518,Albendazole
,2038091,Cmax,"ABZSO was detected from 0.5-0.75 h up to 32 h post-administration, with a Cmax for the zwitterion suspension of 1.21 +/- 0.13 micrograms/ml and AUC of 18.55 +/- 1.45 micrograms.h/ml, respectively, which were significantly higher (P less than 0.01) than the Cmax (0.67 +/- 0.12 micrograms/ml) and AUC (8.57 +/- 0.91 micrograms.h/ml) for the trisamine solution.",Pharmacokinetic profiles of netobimin metabolites after oral administration of zwitterion and trisamine formulations of netobimin to cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038091/),[μg] / [ml],0.67,248559,DB00518,Albendazole
,2038091,AUC,"ABZSO was detected from 0.5-0.75 h up to 32 h post-administration, with a Cmax for the zwitterion suspension of 1.21 +/- 0.13 micrograms/ml and AUC of 18.55 +/- 1.45 micrograms.h/ml, respectively, which were significantly higher (P less than 0.01) than the Cmax (0.67 +/- 0.12 micrograms/ml) and AUC (8.57 +/- 0.91 micrograms.h/ml) for the trisamine solution.",Pharmacokinetic profiles of netobimin metabolites after oral administration of zwitterion and trisamine formulations of netobimin to cattle. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038091/),[h·μg] / [ml],8.57,248560,DB00518,Albendazole
,2038091,Cmax,"The zwitterion suspension resulted in a Cmax (2.91 +/- 0.10 micrograms/ml) and AUC (51.67 +/- 1.95 micrograms.h/ml) for ABZSO2, which were significantly higher (P less than 0.01) than those obtained for the trisamine solution (Cmax = 1.67 +/- 0.11 micrograms/ml and AUC = 22.77 +/- 1.09 micrograms.h/ml).",Pharmacokinetic profiles of netobimin metabolites after oral administration of zwitterion and trisamine formulations of netobimin to cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038091/),[μg] / [ml],2.91,248561,DB00518,Albendazole
,2038091,AUC,"The zwitterion suspension resulted in a Cmax (2.91 +/- 0.10 micrograms/ml) and AUC (51.67 +/- 1.95 micrograms.h/ml) for ABZSO2, which were significantly higher (P less than 0.01) than those obtained for the trisamine solution (Cmax = 1.67 +/- 0.11 micrograms/ml and AUC = 22.77 +/- 1.09 micrograms.h/ml).",Pharmacokinetic profiles of netobimin metabolites after oral administration of zwitterion and trisamine formulations of netobimin to cattle. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038091/),[h·μg] / [ml],51.67,248562,DB00518,Albendazole
,2038091,Cmax,"The zwitterion suspension resulted in a Cmax (2.91 +/- 0.10 micrograms/ml) and AUC (51.67 +/- 1.95 micrograms.h/ml) for ABZSO2, which were significantly higher (P less than 0.01) than those obtained for the trisamine solution (Cmax = 1.67 +/- 0.11 micrograms/ml and AUC = 22.77 +/- 1.09 micrograms.h/ml).",Pharmacokinetic profiles of netobimin metabolites after oral administration of zwitterion and trisamine formulations of netobimin to cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038091/),[μg] / [ml],1.67,248563,DB00518,Albendazole
,2038091,AUC,"The zwitterion suspension resulted in a Cmax (2.91 +/- 0.10 micrograms/ml) and AUC (51.67 +/- 1.95 micrograms.h/ml) for ABZSO2, which were significantly higher (P less than 0.01) than those obtained for the trisamine solution (Cmax = 1.67 +/- 0.11 micrograms/ml and AUC = 22.77 +/- 1.09 micrograms.h/ml).",Pharmacokinetic profiles of netobimin metabolites after oral administration of zwitterion and trisamine formulations of netobimin to cattle. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038091/),[h·μg] / [ml],22.77,248564,DB00518,Albendazole
,2038091,ratio of AUC,The ratio of AUC for ABZSO2/ABZSO was 2.92 +/- 0.26 (zwitterion) and 2.80 +/- 0.20 (trisamine).,Pharmacokinetic profiles of netobimin metabolites after oral administration of zwitterion and trisamine formulations of netobimin to cattle. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038091/),,2.92,248565,DB00518,Albendazole
,2038091,ratio of AUC,The ratio of AUC for ABZSO2/ABZSO was 2.92 +/- 0.26 (zwitterion) and 2.80 +/- 0.20 (trisamine).,Pharmacokinetic profiles of netobimin metabolites after oral administration of zwitterion and trisamine formulations of netobimin to cattle. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038091/),,2.80,248566,DB00518,Albendazole
,18053296,midpoint,"The midpoint for the pharmacologically active metabolite, albendazole sulphoxide, in the circulatory compartment was around 0.6 mug ml- 1 both in parasitized and naïve goats.",Kinetic disposition of albendazole in goats subclinically infected with gastrointestinal nematodes vis-à-vis naive animals following oral and intraruminal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18053296/),1·ml-·μg,0.6,250514,DB00518,Albendazole
higher,31230255,AUC0-24/MIC90 ratio,"However, M. haemolytica affected the pharmacokinetics of marbofloxacin in diseased lambs, AUC0-24/MIC90 ratio was not found to be higher than 125, but Cmax/MIC90 ratios was found to be higher than 10 for an MIC value of 0.25 μg/mL in all groups.",The effects of Mannheimia haemolytica and albendazole on marbofloxacin pharmacokinetics in lambs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31230255/),,125,253044,DB00518,Albendazole
higher,31230255,Cmax/MIC90 ratios,"However, M. haemolytica affected the pharmacokinetics of marbofloxacin in diseased lambs, AUC0-24/MIC90 ratio was not found to be higher than 125, but Cmax/MIC90 ratios was found to be higher than 10 for an MIC value of 0.25 μg/mL in all groups.",The effects of Mannheimia haemolytica and albendazole on marbofloxacin pharmacokinetics in lambs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31230255/),,10,253045,DB00518,Albendazole
,31230255,MIC,"However, M. haemolytica affected the pharmacokinetics of marbofloxacin in diseased lambs, AUC0-24/MIC90 ratio was not found to be higher than 125, but Cmax/MIC90 ratios was found to be higher than 10 for an MIC value of 0.25 μg/mL in all groups.",The effects of Mannheimia haemolytica and albendazole on marbofloxacin pharmacokinetics in lambs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31230255/),[μg] / [ml],0.25,253046,DB00518,Albendazole
≤,31230255,MIC,"The marbofloxacin dose described in this study may not be effective for the treatment of infections due to M. haemolytica in lambs, with MIC ≤ 0.25 μg/mL.",The effects of Mannheimia haemolytica and albendazole on marbofloxacin pharmacokinetics in lambs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31230255/),[μg] / [ml],0.25,253047,DB00518,Albendazole
,19916998,concentration,The mean concentration of serum ABZ was 63.7 +/- 11.9 ng ml(-1).,Albendazole and its metabolites in the breast milk of lactating women following a single oral dose of albendazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19916998/),[ng] / [ml],63.7,258502,DB00518,Albendazole
,19916998,C(max),"The pharmacokinetic parameters for ABSX were calculated as follows: 351.9 +/- 32.4 ng ml(-1), 6.9 +/- 0.5 h, 12.4 +/- 2.2 h and 5190.3 +/- 482.8 ng*h ml(-1) for C(max), T(max), t((1/2)) and AUC(0-36), respectively.",Albendazole and its metabolites in the breast milk of lactating women following a single oral dose of albendazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19916998/),[ng] / [ml],351.9,258503,DB00518,Albendazole
,19916998,C(max),"The pharmacokinetic parameters for ABSX were calculated as follows: 351.9 +/- 32.4 ng ml(-1), 6.9 +/- 0.5 h, 12.4 +/- 2.2 h and 5190.3 +/- 482.8 ng*h ml(-1) for C(max), T(max), t((1/2)) and AUC(0-36), respectively.",Albendazole and its metabolites in the breast milk of lactating women following a single oral dose of albendazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19916998/),h,6.9,258504,DB00518,Albendazole
,19916998,C(max),"The pharmacokinetic parameters for ABSX were calculated as follows: 351.9 +/- 32.4 ng ml(-1), 6.9 +/- 0.5 h, 12.4 +/- 2.2 h and 5190.3 +/- 482.8 ng*h ml(-1) for C(max), T(max), t((1/2)) and AUC(0-36), respectively.",Albendazole and its metabolites in the breast milk of lactating women following a single oral dose of albendazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19916998/),h,12.4,258505,DB00518,Albendazole
,19916998,C(max),"The pharmacokinetic parameters for ABSX were calculated as follows: 351.9 +/- 32.4 ng ml(-1), 6.9 +/- 0.5 h, 12.4 +/- 2.2 h and 5190.3 +/- 482.8 ng*h ml(-1) for C(max), T(max), t((1/2)) and AUC(0-36), respectively.",Albendazole and its metabolites in the breast milk of lactating women following a single oral dose of albendazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19916998/),[h·ng] / [ml],5190.3,258506,DB00518,Albendazole
,19916998,T(max),"The pharmacokinetic parameters for ABSX were calculated as follows: 351.9 +/- 32.4 ng ml(-1), 6.9 +/- 0.5 h, 12.4 +/- 2.2 h and 5190.3 +/- 482.8 ng*h ml(-1) for C(max), T(max), t((1/2)) and AUC(0-36), respectively.",Albendazole and its metabolites in the breast milk of lactating women following a single oral dose of albendazole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19916998/),[h·ng] / [ml],5190.3,258507,DB00518,Albendazole
,19916998,t((1/2)),"The pharmacokinetic parameters for ABSX were calculated as follows: 351.9 +/- 32.4 ng ml(-1), 6.9 +/- 0.5 h, 12.4 +/- 2.2 h and 5190.3 +/- 482.8 ng*h ml(-1) for C(max), T(max), t((1/2)) and AUC(0-36), respectively.",Albendazole and its metabolites in the breast milk of lactating women following a single oral dose of albendazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19916998/),[h·ng] / [ml],5190.3,258508,DB00518,Albendazole
,19916998,AUC(0-36),"The pharmacokinetic parameters for ABSX were calculated as follows: 351.9 +/- 32.4 ng ml(-1), 6.9 +/- 0.5 h, 12.4 +/- 2.2 h and 5190.3 +/- 482.8 ng*h ml(-1) for C(max), T(max), t((1/2)) and AUC(0-36), respectively.",Albendazole and its metabolites in the breast milk of lactating women following a single oral dose of albendazole. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19916998/),[h·ng] / [ml],5190.3,258509,DB00518,Albendazole
,19916998,milk-to-serum ratios,"The milk-to-serum ratios (range) for ABZ and ABSX were 0.9 (0.2-6.5) and 0.6 (0.1-1.5), respectively.",Albendazole and its metabolites in the breast milk of lactating women following a single oral dose of albendazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19916998/),,0.9,258510,DB00518,Albendazole
,19916998,milk-to-serum ratios,"The milk-to-serum ratios (range) for ABZ and ABSX were 0.9 (0.2-6.5) and 0.6 (0.1-1.5), respectively.",Albendazole and its metabolites in the breast milk of lactating women following a single oral dose of albendazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19916998/),,0.6,258511,DB00518,Albendazole
,12367706,Mobile phase flow rate,Mobile phase flow rate was 1.0 ml/min.,HPLC assay for albendazole and metabolites in human plasma for clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12367706/),[ml] / [min],1.0,258590,DB00518,Albendazole
,12367706,retention times,"The retention times of albendazole, ABZSO, ABZSO2, and the internal standard were approximately 24.4, 7.9, 13.4, and 11.3 min, respectively.",HPLC assay for albendazole and metabolites in human plasma for clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12367706/),min,24.4,258591,DB00518,Albendazole
,12367706,retention times,"The retention times of albendazole, ABZSO, ABZSO2, and the internal standard were approximately 24.4, 7.9, 13.4, and 11.3 min, respectively.",HPLC assay for albendazole and metabolites in human plasma for clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12367706/),min,7.9,258592,DB00518,Albendazole
,12367706,retention times,"The retention times of albendazole, ABZSO, ABZSO2, and the internal standard were approximately 24.4, 7.9, 13.4, and 11.3 min, respectively.",HPLC assay for albendazole and metabolites in human plasma for clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12367706/),min,13.4,258593,DB00518,Albendazole
,12367706,retention times,"The retention times of albendazole, ABZSO, ABZSO2, and the internal standard were approximately 24.4, 7.9, 13.4, and 11.3 min, respectively.",HPLC assay for albendazole and metabolites in human plasma for clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12367706/),min,11.3,258594,DB00518,Albendazole
,12367706,Total run time,Total run time was 30 min.,HPLC assay for albendazole and metabolites in human plasma for clinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12367706/),min,30,258595,DB00518,Albendazole
,32266168,Cmax,"The plasma concentration of S6 administered by both methods was very low, with the Cmax being only 1 ng/ml after oral administration and below the detection limit after intramuscular administration.",Pharmacophore-Based Virtual Screening Toward the Discovery of Novel Anti-echinococcal Compounds. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32266168/),[ng] / [ml],1,262255,DB00518,Albendazole
,21819410,area under the concentration vs time curve (AUC),"While ABZ parent drug was not recovered in the bloodstream, the area under the concentration vs time curve (AUC) of the active ABZ-sulphoxide (ABZSO) metabolite increased significantly (P<0.05) from 21.0 (ABZ(5)) up to 158.6 (ABZ(15)) and 389.7 μg·h/mL (ABZ(45)), which indicates some type of nonproportionality in the relationship between dose level and drug systemic exposure.",Dose-dependent systemic exposure of albendazole metabolites in lambs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21819410/),[h·μg] / [ml],21.0,262381,DB00518,Albendazole
,21819410,area under the concentration vs time curve (AUC),"While ABZ parent drug was not recovered in the bloodstream, the area under the concentration vs time curve (AUC) of the active ABZ-sulphoxide (ABZSO) metabolite increased significantly (P<0.05) from 21.0 (ABZ(5)) up to 158.6 (ABZ(15)) and 389.7 μg·h/mL (ABZ(45)), which indicates some type of nonproportionality in the relationship between dose level and drug systemic exposure.",Dose-dependent systemic exposure of albendazole metabolites in lambs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21819410/),[h·μg] / [ml],158.6,262382,DB00518,Albendazole
,21819410,area under the concentration vs time curve (AUC),"While ABZ parent drug was not recovered in the bloodstream, the area under the concentration vs time curve (AUC) of the active ABZ-sulphoxide (ABZSO) metabolite increased significantly (P<0.05) from 21.0 (ABZ(5)) up to 158.6 (ABZ(15)) and 389.7 μg·h/mL (ABZ(45)), which indicates some type of nonproportionality in the relationship between dose level and drug systemic exposure.",Dose-dependent systemic exposure of albendazole metabolites in lambs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21819410/),[h·μg] / [ml],389.7,262383,DB00518,Albendazole
,14522595,intestinal clearance,The intestinal clearance of ABZSO was 0.106+/-0.010 ml/min.,Ginseng increases intestinal elimination of albendazole sulfoxide in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14522595/),[ml] / [min],0.106,263036,DB00518,Albendazole
,14522595,clearance,Systemic co-administration of ginseng (10 mg/kg i.v.) increased significantly (P<0.05) the clearance of ABZSO (0.132+/-0.005 ml/min).,Ginseng increases intestinal elimination of albendazole sulfoxide in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14522595/),[ml] / [min],0.132,263037,DB00518,Albendazole
,28115181,overall clinical drug efficacies,"The observed overall clinical drug efficacies were 48% (IVM alone), 94% (RBZ alone) and 98% (IVM+RBZ).",Resistant nematodes in cattle: Pharmaco-therapeutic assessment of the ivermectin- ricobendazole combination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28115181/),%,48,264947,DB00518,Albendazole
,28115181,overall clinical drug efficacies,"The observed overall clinical drug efficacies were 48% (IVM alone), 94% (RBZ alone) and 98% (IVM+RBZ).",Resistant nematodes in cattle: Pharmaco-therapeutic assessment of the ivermectin- ricobendazole combination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28115181/),%,94,264948,DB00518,Albendazole
,28115181,overall clinical drug efficacies,"The observed overall clinical drug efficacies were 48% (IVM alone), 94% (RBZ alone) and 98% (IVM+RBZ).",Resistant nematodes in cattle: Pharmaco-therapeutic assessment of the ivermectin- ricobendazole combination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28115181/),%,98,264949,DB00518,Albendazole
,27480864,50% inhibitory concentration [IC50],CYP1A2 showed a 2.6-fold increased inhibition by albendazole-oxantel pamoate (50% inhibitory concentration [IC50] = 3.1 μM) and a 3.9-fold increased inhibition by albendazole sulfoxide-mebendazole (IC50 = 3.8 μM) compared to the single drugs.,"In Vitro and In Vivo Drug Interaction Study of Two Lead Combinations, Oxantel Pamoate plus Albendazole and Albendazole plus Mebendazole, for the Treatment of Soil-Transmitted Helminthiasis. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27480864/),μM,3.1,267180,DB00518,Albendazole
,27480864,IC50,CYP1A2 showed a 2.6-fold increased inhibition by albendazole-oxantel pamoate (50% inhibitory concentration [IC50] = 3.1 μM) and a 3.9-fold increased inhibition by albendazole sulfoxide-mebendazole (IC50 = 3.8 μM) compared to the single drugs.,"In Vitro and In Vivo Drug Interaction Study of Two Lead Combinations, Oxantel Pamoate plus Albendazole and Albendazole plus Mebendazole, for the Treatment of Soil-Transmitted Helminthiasis. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27480864/),μM,3.8,267181,DB00518,Albendazole
below,27480864,bioavailability,"Oxantel pamoate could not be quantified, translating to a bioavailability below 0.025% in rats.","In Vitro and In Vivo Drug Interaction Study of Two Lead Combinations, Oxantel Pamoate plus Albendazole and Albendazole plus Mebendazole, for the Treatment of Soil-Transmitted Helminthiasis. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27480864/),%,0.025,267182,DB00518,Albendazole
,10722069,recoveries,"The mean recoveries for albendazole and its metabolites were about 70 and 65%, respectively.",Determination of albendazole and its main metabolites in ovine plasma by liquid chromatography with dialysis as an integrated sample preparation technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722069/),%,70,267460,DB00518,Albendazole
,10722069,recoveries,"The mean recoveries for albendazole and its metabolites were about 70 and 65%, respectively.",Determination of albendazole and its main metabolites in ovine plasma by liquid chromatography with dialysis as an integrated sample preparation technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722069/),%,65,267461,DB00518,Albendazole
,2384908,percentages,"The percentages of total dose excreted in the urine as NTB, ABZ, ABZSO and ABZSO2 were 17.05 (i.r.) and 8.16 (s.c.).",Pharmacokinetic behaviour of netobimin and its metabolites in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2384908/),,17.05,267791,DB00518,Albendazole
,2384908,percentages,"The percentages of total dose excreted in the urine as NTB, ABZ, ABZSO and ABZSO2 were 17.05 (i.r.) and 8.16 (s.c.).",Pharmacokinetic behaviour of netobimin and its metabolites in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2384908/),,8.16,267792,DB00518,Albendazole
,29894001,maximum concentrations,"Only ABZSO and ABZSO2 metabolites were quantified in egg after ABZ single oral administration with maximum concentrations of 0.47 ± 0.08 and 0.30 ± 0.07 μg/ml, respectively.",Albendazole treatment in laying hens: Egg residues and its effects on fertility and hatchability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29894001/),[μg] / [ml],0.47,268490,DB00518,Albendazole
,29894001,maximum concentrations,"Only ABZSO and ABZSO2 metabolites were quantified in egg after ABZ single oral administration with maximum concentrations of 0.47 ± 0.08 and 0.30 ± 0.07 μg/ml, respectively.",Albendazole treatment in laying hens: Egg residues and its effects on fertility and hatchability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29894001/),[μg] / [ml],0.30,268491,DB00518,Albendazole
,29894001,AUCs (areas under the concentration vs. time curve),"The egg residue exposure estimated as AUCs (areas under the concentration vs. time curve) were 100.5 (ABZ), 56.3 (ABZSO) and 141.3 μg hr g-1 (ABZSO2 ).",Albendazole treatment in laying hens: Egg residues and its effects on fertility and hatchability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29894001/),[h·μg] / [g],100.5,268492,DB00518,Albendazole
,29894001,AUCs (areas under the concentration vs. time curve),"The egg residue exposure estimated as AUCs (areas under the concentration vs. time curve) were 100.5 (ABZ), 56.3 (ABZSO) and 141.3 μg hr g-1 (ABZSO2 ).",Albendazole treatment in laying hens: Egg residues and its effects on fertility and hatchability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29894001/),[h·μg] / [g],56.3,268493,DB00518,Albendazole
,29894001,AUCs (areas under the concentration vs. time curve),"The egg residue exposure estimated as AUCs (areas under the concentration vs. time curve) were 100.5 (ABZ), 56.3 (ABZSO) and 141.3 μg hr g-1 (ABZSO2 ).",Albendazole treatment in laying hens: Egg residues and its effects on fertility and hatchability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29894001/),[h·μg] / [g],141.3,268494,DB00518,Albendazole
,12207631,AUC(+)/AUC(-) ratio,The CSF AUC(+)/AUC(-) ratio was 3.4 for patients receiving albendazole every 12 h.,Enantioselective distribution of albendazole metabolites in cerebrospinal fluid of patients with neurocysticercosis. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207631/),,3.4,270659,DB00518,Albendazole
,12207631,elimination half-life,The elimination half-life of both ASOX enantiomers in CSF was 2.5 h.,Enantioselective distribution of albendazole metabolites in cerebrospinal fluid of patients with neurocysticercosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207631/),h,2.5,270660,DB00518,Albendazole
,12207631,AUC(,ASOX was the predominant metabolite in the CSF compared with ASON; the CSF AUC(ASOX)/AUC(ASON) ratio was approximately 20 and the elimination half-life of ASON in CSF was 2.6 h.,Enantioselective distribution of albendazole metabolites in cerebrospinal fluid of patients with neurocysticercosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207631/),,20,270661,DB00518,Albendazole
,12207631,elimination half-life,ASOX was the predominant metabolite in the CSF compared with ASON; the CSF AUC(ASOX)/AUC(ASON) ratio was approximately 20 and the elimination half-life of ASON in CSF was 2.6 h.,Enantioselective distribution of albendazole metabolites in cerebrospinal fluid of patients with neurocysticercosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12207631/),h,2.6,270662,DB00518,Albendazole
,10423586,Maximum plasma levels,Maximum plasma levels for albendazole sulphoxide ranged from 0.2-1.0 microg/mL.,Clinical pharmacokinetics of albendazole in children with neurocysticercosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423586/),[μg] / [ml],0.2-1.0,271950,DB00518,Albendazole
,10423586,half-life,The half-life for albendazole sulphoxide was from 2.3-8.3 hours and mean residence time values were from 5.,Clinical pharmacokinetics of albendazole in children with neurocysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423586/),h,2.3-8.3,271951,DB00518,Albendazole
,10423586,mean residence time,The half-life for albendazole sulphoxide was from 2.3-8.3 hours and mean residence time values were from 5.,Clinical pharmacokinetics of albendazole in children with neurocysticercosis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423586/),,5,271952,DB00518,Albendazole
,26566193,maximum concentration,"Plasma albendazole sulphoxide metabolite, the anthelmintically active moiety, reached its maximum concentration of 0.322 ± 0.045 μg ml- 1 and 0.384 ± 0.013 μg ml- 1 at 18 h and 24 h after administration of albendazole alone and co-administration of albendazole with piperonyl butoxide, respectively.",Efficacy of pharmacokinetic interactions between piperonyl butoxide and albendazole against gastrointestinal nematodiasis in goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26566193/),1·ml-·μg,0.322,274251,DB00518,Albendazole
,26566193,maximum concentration,"Plasma albendazole sulphoxide metabolite, the anthelmintically active moiety, reached its maximum concentration of 0.322 ± 0.045 μg ml- 1 and 0.384 ± 0.013 μg ml- 1 at 18 h and 24 h after administration of albendazole alone and co-administration of albendazole with piperonyl butoxide, respectively.",Efficacy of pharmacokinetic interactions between piperonyl butoxide and albendazole against gastrointestinal nematodiasis in goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26566193/),1·ml-·μg,0.384,274252,DB00518,Albendazole
,26566193,ED50,"The ED50 for egg hatch was 0.196, indicating suspected resistance to benzimidazole anthelmintics.",Efficacy of pharmacokinetic interactions between piperonyl butoxide and albendazole against gastrointestinal nematodiasis in goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26566193/),,0.196,274253,DB00518,Albendazole
